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Abstract 
 
Introduction 
Biliary and pancreatic cancers are associated with poor prognosis and high 
mortality. A variety of genetic and environmental factors have been 
implicated as possible causes of these cancers. New epidemiological studies 
are looking into the possible role of heavy metals such as lead, chromium, 
nickel and cadmium as carcinogens. Studies from areas of wide 
geographical differences such as Egypt, USA and India have reported a 
possible association of heavy metals such as lead and cadmium with 
pancreato-biliary malignancy. These studies were from areas of significant 
environmental pollution with these metals due to the proximity of heavy 
industry or mining activities. No association has been demonstrated between 
metal exposure and pancreato-biliary malignancy in areas of low 
environmental pollution. 
 
Aim  
The aim of this study was to look at a possible association between excretion 
of heavy metals from the biliary tract and pancreato-biliary malignancy in an 
industrial area in the North-East of England.  
 
Materials and Methods 
Patients with malignant biliary obstruction admitted to a tertiary referral 
centre were identified prospectively. Bile was collected either during 
endoscopic retrograde cholangiography (ERC), percutaneous transhepatic 
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cholangiography (PTC) or during biliary tract surgery. Bile was also collected 
from patients with benign biliary disease to act as controls. The bile samples 
were analyzed for concentrations of lead, copper, zinc, cadmium, chromium 
and nickel using atomic absorption spectrometry after pre-treatment by the 
acid digestion method. The mean levels of every metal in the study groups 
(biliary malignancy and pancreatic malignancy) and the control group were 
compared by using SPSS 16© (SPSS Inc) statistical software. 
 
It was uncertain whether there would be a measurable quantity of heavy 
metals in the bile collected during the above procedures and therefore it was 
felt necessary to perform a small pilot study to standardize the methods and 
address any possible difficulties.  
 
Results 
Bile samples collected from 107 patients over a period of 18 months were 
included in this study. As part of the pilot study two different methods of 
purification of bile (acid digestion vs syringe filtration) were evaluated and 
acid digestion was chosen as a more reliable method. For the main study, 
after exclusion due to inadequate volume of sample, a total of 127 bile 
samples from 98 patients (43 male, 55 female, median age 65.82 years, 
range 20-82 years) were analyzed. On final analysis, the malignant group 
comprised of 3 subgroups: pancreatic cancer, biliary cancer and 
periampullary cancer. Results from these 3 groups were compared with 
those from the benign control group. The groups were sex-matched but there 
was a significant difference in age distribution between the benign and 
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malignant groups (p<0.001). Bile samples were obtained from both 
gallbladder (GB) and common bile duct (CBD) in 33 patients and from either 
of these sources in the remainder. There was a strong positive correlation 
between the concentration of each metal when obtained from either GB or 
CBD.  
 
The main results of this study have shown that copper was present at 
significantly higher levels in the benign control group (p=0.004) and that 
cadmium was present at significantly higher levels in the malignant groups 
(p=0.02). There was no significant difference amongst the groups for the 
other heavy metals.  
 
Discussion 
Cadmium has been implicated as a possible environmental carcinogen for 
various malignancies, including pancreatic cancer. Most studies that show 
this association are from areas of high environmental pollution. The present 
study supports this association. There is evidence of excess environmental 
exposure to heavy metals, including cadmium, in the North-East of England. 
This exposure is mainly in relation to mining activities in the past in this 
region and is mainly noticed downstream along the rivers draining the areas 
with significant mining history. The results of this study support the possible 
association between heavy metal exposure and pancreatic and biliary 
malignancy. Further research is needed to establish the specific carcinogenic 
role of heavy metals such as cadmium in pancreato-biliary malignancies. 
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1. INTRODUCTION 
Morphology of biliary and pancreatic cancer 
 
Biliary and pancreatic cancers form a group of diseases that has always 
been challenging for the clinician. They present late and are difficult to 
diagnose. Once diagnosed, they carry a poor prognosis because surgery is 
the only curative option for most of these tumours and success of radical 
surgery depends on detecting them early. Effective adjuvant treatment for 
pancreato-biliary cancers is the subject of scientific research and clinical 
trials. Often described together because of their usual adverse prognosis, 
biliary and pancreatic cancers actually form a very heterogeneous group of 
malignancies with different aetiologies and clinical outcome. 
 
For ease of discussion, pancreato-biliary cancers can be divided into the 
following broad headings:  
1. Bile duct cancer  
a. Intra-hepatic (involving biliary tree within the liver) 
b. Extra-hepatic (involving biliary tree outside the liver) 
i. Hilar 
ii. Middle 
iii. Distal 
2. Gallbladder cancer 
3. Pancreatic cancer 
a. Pancreatic ductal carcinoma 
b. Peri-ampullary carcinoma 
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Figure 1.1: Morphological classification of biliary cancer (CCA – cholangiocarcinoma) 
(Lazaridis and Gores, 2005) 
 
 
The above classification is entirely based on the anatomical location of the 
lesion in the biliary tree (Figure 1.1). Two thirds of all cholangiocarcinomas 
are of the extra-hepatic type and 60% of all extra-hepatic 
cholangiocarcinomas are of the proximal hilar type (Klatskin tumour) 
(Klatskin, 1965). This is again morphologically classified into several types by 
the Bismuth-Corlette classification (Figure 1.2). 
 Type I: Tumours below the confluence of the left and right hepatic ducts.  
 Type II: Tumours reaching the confluence but not involving left or right 
hepatic ducts. 
 Type III: Tumours occluding the common hepatic duct and either the right 
(IIIa) or the left (IIIb) hepatic duct.  
 Type IV: Tumours that are multi-centric or involving both right and left 
hepatic ducts. 
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Figure 1.2: Bismuth-Corlette classification of biliary tumours 
 
Pancreatic tumours can be classified into primary ductal tumours and peri-
ampullary carcinoma depending on their origin. Although they are often 
grouped together and clinically present in a similar pattern, pancreatic ductal 
adenocarcinomas and peri-ampullary tumours have very different prognosis. 
Peri-ampullary tumours are classically defined as tumours arising from within 
2 centimetres from the Ampulla of Vater. They can arise from epithelium of 
distal bile duct, duodenal mucosa or ampullary epithelium.  
Pathology of biliary and pancreatic cancer 
Cholangiocarcinoma 
Tumours of the extra-hepatic biliary tree are found mainly in 3 sites.  
1. Proximal to junction of cystic duct including the hilar region 
2. Distal to cystic duct (mid third) 
3. Lower end of common bile duct (distal third) 
 16 
The usual appearance of proximal and hilar lesions (Klatskin 1965) (Klatskin, 
1965) is that of a sclerosing with an increase in ductal wall thickness. It often 
extends into the surrounding liver tissue as a mass-forming lesion. Based on 
computerised tomographic (CT) scanning, several growth patterns have 
been proposed, i.e. infiltrative and exophytic and the latter is subdivided into 
nodular and periductal types. Occasionally, proximal tumours are polypoid 
and protrude into the lumen of the bile duct. Usually they can be clearly 
demarcated from the surrounding hepatic parenchyma on microscopy. 
Tumours in the mid third are generally discrete tumours, causing thickening 
of the ductal wall, but often presents as a sharply demarcated, spherical 
mass. The tumours in the distal 2cm of the common bile duct are papillary 
adenocarcinoma and are usually quite friable. Most ductal tumours fall into 
these three categories, with annular sclerosing tumours proximally, globular 
or nodular sclerosing type in the mid-region and papillary tumour at the lower 
third.  
 
Microscopically the tumours are generally adenocarcinomas.  Several 
histological variants of cholangiocarcinomas have been reported. They 
comprise distinct forms of adenocarcinomas (papillary, intestinal, mucinous, 
clear cell, signet cell and adenosquamous types), and squamous cell, small 
cell and undifferentiated carcinomas. A distinct variant associated with 
hepatolithiasis and recurrent pyogenic cholangitis is mucin-producing 
cholangiocarcinoma, which has a better prognosis. 
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Gallbladder Cancer 
As with most tumours, gall bladder epithelium progresses from dysplasia to 
carcinoma in-situ to invasive carcinoma. Severe dysplasia and carcinoma in 
situ is identified in more than 90% of cases of gallbladder carcinoma. It is 
likely that areas of dysplasia and carcinoma in situ are missed in routine 
histological examination following cholecystectomy, as there are no 
associated macroscopic characteristics that would target an area for 
histological examination. The rate of progression of precursor lesions to 
invasive carcinoma is about 15 years (Albores-Saavedra et al., 1986). 
 
Carcinomas are difficult to distinguish from chronic cholecystitis at early 
stages and are often found incidentally following routine cholecystectomy. 
Nearly 60% of tumours originate in the fundus of the gallbladder, 30% in the 
body and 10% in the neck (Albores-Saavedra et al., 1986). Macroscopically 
the tumours can be classified as infiltrative, nodular, combined nodular-
infiltrative, papillary and combined papillary-infiltrative forms.  The most 
common forms are the infiltrative or nodular-infiltrative forms.  
 
The histological classification of malignant tumours of gallbladder is given in 
the following table. In general, malignant tumours of the gallbladder carry a 
very poor prognosis. Majority of them are adenocarcinoma and the other 
varieties are extremely rare (Table 1.1). The only histological type with 
definite prognostic significance is the papillary adenocarcinoma, which has 
significantly better survival compared to all other histological types.  
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M al ignant  ep i the l ia l  tumours           M al ignant  mesenchymal  tumour 
Adenocarcinoma                                                 Embryonal rhabdomyosarcoma 
 Well differentiated                                               Leiomyosarcoma 
 Papillary                                                              Malignant fibrous histiocytoma 
 Intestinal type                                                      Angiosarcoma 
 Pleomorphic giant cell                                  
 Poorly-differentiated, small cell 
 Signet ring cell 
 Clear cell 
 
Squamous 
 
Adeno-squamous 
 
Oat cell carcinoma 
 
Table 1.1: Classification of malignant tumours of gallbladder (Albores-Saavedra et al., 
1986) 
 
Pancreatic and periampullary carcinoma 
Pancreatic cancer, especially those involving the head of pancreas and 
periampullary region, is actually a combination of different pathological 
entities with different presentation, behaviour and outcome. The most 
common malignant pancreatic tumour is pancreatic ductal adenocarcinoma. 
However, it is often difficult to diagnose whether or not a lesion situated in 
the head of pancreas is an ampullary lesion, duodenal lesion, a distal bile 
duct lesion or an islet cell tumour.  Cystic neoplasms, both serous and 
mucinous cystadenoma and cystadenocarcinoma are more common than 
previously suspected and should be proactively looked for so that they can 
be resected where appropriate. Pathological classification of pancreatic and 
periampullary tumours is given in the table (Table 1.2). 
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Benign pancreatic tumours Cystadenoma 
 Serous 
 Mucinous 
 Intraductal papillary-mucinous 
Cystic teratoma 
Adenoma 
 Ampulla 
 Duodenum 
Malignant pancreatic tumours Adenocarcinoma 
 Mucinous 
 Signet ring cell 
 Adenosquamous 
 Anaplastic 
 Mixed ductal-endocrine 
 Duodenal adenocarcinomas 
 Ampullary carcinoma 
 Distal bile duct carcinoma 
Cystadenocarcinoma 
 Serous 
 Mucinous 
 Intraductal papillary 
Giant cell 
Acinar cell 
Pancreatoblastoma 
 
 
Table 1.2: Classification of tumours of exocrine pancreas and peripancreatic 
area(Kloppel and Luttges, 2001).  
 
Pancreato-biliary malignancy – prognosis & worldwide trends in 
mortality  
 
Pancreato-biliary malignancies have always been a difficult disease to treat 
due to their late presentation, poor sensitivity to conventional adjuvant 
treatments after surgery and our inability to prevent and detect early tumour 
formation. Their aetiology also remains poorly understood. Cancer of the 
pancreas is an important cause of cancer related mortality in the western 
world and account for nearly 30,000 deaths in the United States per year. It 
probably has the worst survival amongst the major common malignancies; 
the average overall survival after diagnosis is less than 6 months and less 
than 2% patients survive up to 5 years (Bray et al., 2002). 
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Bile duct cancer or cholangiocarcinoma as a pathological entity was reported 
for the first time by Durand-Fardel in 1840 (Olnes and Erlich, 2004). Although 
it comprises only 10% - 15% of hepatobiliary neoplasms, its incidence is 
definitely increasing, especially in the Western world (Shaib and El-Serag, 
2004, Gores, 2003, Khan et al., 2002). The disease is difficult to diagnose 
and the prognosis is poor due to late presentation and lack of effective non-
surgical treatment (Khan et al., 2005). Most of the patients with 
cholangiocarcinoma present with unresectable disease and die within a year 
of diagnosis. Death is due to liver failure, recurrent sepsis secondary to 
biliary obstruction and cancer cachexia (Carriaga and Henson, 1995). Overall 
survival rate, including those undergoing curative resection, is poor, with less 
than 5% overall survival at 5 years, similar to pancreatic cancer. In spite of 
advances in diagnostic modalities and surgical treatment, the overall 
prognosis of this disease has not significantly changed in the last 30 years 
(Shaib and El-Serag, 2004). Cholangiocarcinoma arises from the ductular 
epithelium of either intrahepatic or extrahepatic biliary tree, including the 
gallbladder. Aetiology of this disease remains poorly understood. Risk factors 
seem to differ according to the anatomical location of the tumour. 
Intrahepatic cholangiocarcinomas are highly prevalent in certain regions like 
Thailand and other Southeast Asian countries (Green A, 1991). Because 
parasitic biliary infection is endemic to these regions, liver fluke infection and 
chronic biliary tract inflammation are considered strong risk factors for 
cholangiocarcinoma (Patel, 2002, Flavell, 1981, Haswell-Elkins MR, 1994). 
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Other possible aetiology, including genetic and environmental factors have 
been investigated but the actual pathogenesis remains obscure. 
 
Although cholangiocarcinoma is a rare neoplasm, its incidence has increased 
in the past three decades (Shaib and El-Serag, 2004). A recent increase in 
intrahepatic, but not extrahepatic biliary tumours have been reported from the 
United States (Patel, 2001). Similar increases in incidence of the intrahepatic 
tumour have been reported from other parts of the world including Europe 
and China (Hsing AW, 1998, Taylor-Robinson et al., 2001). However, the 
majority of the new cases diagnosed continue to be the extrahepatic variety. 
In the United States, approximately 5000 new cases are diagnosed every 
year, two thirds of which are extrahepatic lesions (Lazaridis and Gores, 2005, 
Shaib and El-Serag, 2004). Recent studies have indicated that intrahepatic 
and extrahepatic cholangiocarcinomas have a distinct epidemiology and the 
epidemiology of gallbladder cancer also has some unique features differing 
from other extrahepatic cholangiocarcinomas. In the past this distinction was 
not very clearly understood and therefore the reported epidemiological 
observations may not be correct. The intrahepatic cholangiocarcinomas were 
often combined with primary hepatocellular carcinoma and therefore the 
global increase in incidence and mortality from intrahepatic 
cholangiocarcinoma may partly be due to recognition of this disease as a 
separate entity (Patel, 2002).  
 
A review by Patel et al (Patel, 2002) showed that there has been a global 
increase in mortality from intrahepatic cholangiocarcinoma with the greatest 
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increase noted in the Americas, Oceania and Western Europe (Figure 1.3). 
Central and Northern Europe have seen a less marked increase in mortality 
and same was seen in Asia and Middle East. However, data from regions of 
high incidence of intrahepatic cholangiocarcinoma such as Thailand and 
other South-East Asian countries were not included in this analysis.  It could 
be concluded from the study that there has been increase in mortality from 
this disease in areas of low prevalence.  
 
 
Figure 1.3: Regional differences in the mean estimated annual percentage change 
(EAPC) in age-adjusted (1970 World standard population) gender specific mortality 
rates from intrahepatic biliary tract tumours (top) and extrahepatic biliary tract 
tumours (bottom) (Patel, 2002) 
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Epidemiology 
Cholangiocarcinoma 
Cholangiocarcinoma accounts for 3% of all gastrointestinal cancers (Vauthey 
and Blumgart, 1994) and is the second commonest primary liver tumour 
(Khan et al., 2002, Vauthey and Blumgart, 1994). In the United States, the 
age-adjusted incidence of intrahepatic cholangiocarcinoma, the definition of 
which included peri-hilar lesions, increased from 0.32 in 100,000 in 1975-
1979 to 0.85 in 100,000 in 1995-1999. On the other hand, the incidence of 
extrahepatic cholangiocarcinoma declined from 1.08 in 100,000 in 1979 to 
0.82 in 100,1000 in 1982 (Shaib and El-Serag, 2004)(Figure 1.4). Several 
other studies have confirmed similar trends worldwide (Khan et al., 2002, 
Patel, 2001, Patel, 2002, Taylor-Robinson et al., 2001). 
 
 
 
Figure 1.4: Incidence of intra-hepatic and extra-hepatic cholangiocarcinoma in the 
United States from 1975 to 1999. Note that the term intrahepatic cholangiocarcinoma 
includes peri-hilar lesions (Lazaridis and Gores, 2005, Shaib and El-Serag, 2004)). 
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Figure 1.5: International age-standardized mortality rates (ASMR) for intra-hepatic 
cholangiocarcinoma (A) and for gall bladder and extra-hepatic cholangiocarcinoma 
(B) (Khan et al., 2005). 
 
Intra-hepatic cholangiocarcinoma 
The incidence of intra-hepatic cholangiocarcinoma shows significant variation 
worldwide. This probably reflects the influence of local environmental risk 
factors as well as genetic influences of different populations. The highest 
incidence is reported from north-east Thailand (96 per 100,000 men), other 
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South-East Asian countries and China, while Australia has a very low 
incidence of 0.2 per 100,000 men (Shaib and El-Serag, 2004). In recent 
years, an increase in incidence as well as mortality rate has been reported 
from all over the world including Europe, America and Australia (Khan et al., 
2005) (Figure 1.5). In the United Kingdom, intra-hepatic cholangiocarcinoma 
has overtaken hepatocellular carcinoma as the leading cause of death from 
primary liver tumours (Khan et al., 2002, Taylor-Robinson et al., 2001). It 
needs to be investigated whether this increase in incidence is a true increase 
rather than one due to better detection or reclassification of hepatobiliary 
malignancy. Epidemiological studies from the United States show that age-
adjusted incidence rates of intra-hepatic cholangiocarcinoma had increased 
by 165%, from 0·32 per 100 000 during 1975–79 to 0·85 per 100 000 during 
1995–99 (Shaib et al., 2004). As with similar studies from other countries, 
this rise occurred across all age groups, especially in those older than 65 
years, and in both sexes. Increased detection of a tumour is usually 
associated with an increase in the proportion of patients with early stage 
disease, or smaller sized lesions. The rise in intra-hepatic cancer was not 
associated with a significant change in the proportion of early stage cancers, 
histologically confirmed tumours, or smaller sized lesions(Shaib et al., 2004). 
Furthermore, the rising incidence does not seem to reach a plateau, as 
would be expected if it were due to an improvement in diagnostic modalities, 
such as endoscopic retrograde cholangiopancreatography (ERCP), MRI, or 
CT, which have become established practice for several years (Khan et al., 
2002, Shaib and El-Serag, 2004, Taylor-Robinson et al., 2001). Also of note, 
the rise in intra-hepatic tumours is greater than the relative decline in extra-
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hepatic tumours (Khan et al., 2002, Shaib and El-Serag, 2004). These 
factors suggest that the increasing incidence in intra-hepatic cancer is 
probably a true increase. However, the cause for increase in incidence of 
intra-hepatic cholangiocarcinoma remains unclear. The main risk factor for 
this disease in the western world is primary sclerosing cholangitis (PSC) and 
that has shown no significant increase in incidence. Primary sclerosing 
cholangitis is associated with the development of intra-hepatic 
cholangiocarcinoma in younger patients and the increase in incidence of 
intra-hepatic cholangiocarcinoma has mainly affected the older population 
(Khan et al., 2005, Shaib and El-Serag, 2004).  
Extra-hepatic Cholangiocarcinoma & Gallbladder cancer 
There are very few epidemiological data for extra-hepatic 
cholangiocarcinoma. However, incidence and mortality rates seem to be 
declining in many countries (Figure 1.5). Surveillance, Epidemiology and End 
Result (SEER) data from US National Institute of Health suggest that age-
standardized mortality rates for extra-hepatic tumours fell from 0·6 per 100 
000 in 1979 to 0·3 per 100 000 in 1998; and age-standardized incidence 
rates decreased from 1·08 per 100 000 to 0·82 per 100 000 in the same 
period (Patel, 2001, Shaib and El-Serag, 2004). Similar trends have been 
reported worldwide (Khan et al., 2002, Patel, 2002). The data for extra-
hepatic cancer are perhaps more difficult to obtain because gallbladder 
cancers are often combined with extra-hepatic cholangiocarcinoma for ICD 
coding purposes, and gallbladder cancer incidence is known to be falling, 
probably as a result of increasing cholecystectomy rates over the past few 
decades (Khan et al., 2002, Taylor-Robinson et al., 2001). 
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Carcinoma of the gallbladder is a rare malignancy, usually associated with 
late presentation and therefore carries a poor prognosis. Non-metastatic 
lesions carry a 5-year survival rate of 32%, whereas more advanced stages 
have a 1-year survival rate of only 10% (Lazcano-Ponce et al., 2001). It 
affects 1-2 people per 100,000 population in the United States, accounting 
for 2000 to 5000 new cases diagnosed each year (de Groen et al., 1999, 
Fong and Malhotra, 2001). The incidence of this varies in different parts of 
the world, with the highest incidence and mortality occurring in northern 
India, northeastern Europe, and in the native population in North & South 
America. Ethnicity influences the incidence of this disease. In the United 
States, western Native Americans and Hispanic Americans are at an 
increased risk compared to the general US population, while African 
Americans are at an equivalent or slightly decreased risk compared to the 
Caucasian population (Lazcano-Ponce et al., 2001). Increased risk is also 
noted in women in Japan & Israel (Pandey and Shukla, 2003). The ratio 
between affected women to men also varies according to region, ranging 
between 1.5:1 and 6:1 (Lazcano-Ponce et al., 2001, Misra et al., 2003, Yee 
et al., 2002). The risk increases with age, with the maximum incidence 
occurring in the 7th decade (Fong and Malhotra, 2001). 
Pancreatic Cancer 
The incidence of pancreatic cancer has increased steadily in many countries 
for the last century. Mortality doubled in the UK between 1930 and 1970, but 
has risen much more slowly since then and it is the sixth most common 
cancer death in this country. The incidence is higher in Western or 
industrialized countries in general. Pancreatic cancer is rare before the age 
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of 45 years and 80% of cases occur in the 60–80 year age group. A study in 
the West Midlands indicated an age standardised incidence between 1960 
and 1984 of approximately 10 cases per 100 000 population. There seems to 
have been some plateau of the annual incidence reported in this and other 
series. Because the five-year survival of this condition is so poor, incidence 
and mortality rates are virtually identical. Pancreatic cancer has been more 
common in men than women but this is trend is now beginning to change. In 
the USA, the Surveillance, Epidemiology, and End Results (SEER) program 
has shown a fall in the total incidence of pancreatic cancer from 12.3 per 
100, 000 in 1973 to 10.7 per 100 000 in 1999. During the same period, the 
decline in rates for men was from 16.1 per 100 000 population to 12.1 per 
100 000, and for women from 9.6 per 100 000 to 9.5 per 100 000, 
respectively. 
 
Other periampullary tumours (of the ampulla, lower common bile duct, or 
duodenum) can present with similar symptoms and signs to pancreatic 
cancer. Without careful histological evaluation the differential diagnosis of 
tumour types may be impossible. The numbers of periampullary cancers are 
lower than pancreatic cancers, but they are more often resectable, so as 
many as half of pancreatic resections are for these periampullary tumours. 
Risk factors for pancreato-biliary malignancy 
Cholangiocarcinoma 
Most of the identified risk factors for cholangiocarcinoma are associated with 
chronic inflammation and scarring of the biliary epithelium. 
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Primary sclerosing cholangitis 
Primary sclerosing cholangitis is the commonest predisposing condition for 
cholangiocarcinoma in the West. Cholangiocarcinoma rates of 8–40% have 
been reported in patients with primary sclerosing cholangitis in follow up 
studies and liver explant specimens (Shaib and El-Serag, 2004). 
Cholangiocarcinoma in such patients tends to present earlier, in 30–50 year 
age-groups, than in sporadic cases (Pitt et al., 1995). About a third of 
patients with primary sclerosing cholangitis who develop cholangiocarcinoma 
do so within two years of diagnosis and the risk of developing 
cholangiocarcinoma seems unrelated to the duration of the inflammatory 
disease (Bergquist et al., 1998, Broome et al., 1996). Two-thirds of patients 
with primary sclerosing cholangitis have associated inflammatory bowel 
disease, especially ulcerative colitis (Broome et al., 1996). No association 
has been shown between the risk of cholangiocarcinoma and the presence, 
severity, and extent of inflammatory bowel disease in this group of patients 
(Broome et al., 1996, Chalasani et al., 2000).  
Parasitic Infection 
Experimental and epidemiological data suggest a pathogenic association 
between liver fluke infestation, especially Opisthorcis viverrini (and less 
definitively Clonorchis sinensis) and cholangiocarcinoma (Watanapa and 
Watanapa, 2002). Most epidemiological data are from Thailand, which has 
the highest incidence of cholangiocarcinoma worldwide (87 per 100 000 
population) and where an estimated seven million people have 
opisthorchiasis (Watanapa, 1996). Eating undercooked fish infects human 
beings with adult worms inhabiting and laying eggs in the biliary system. 
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Apart from a strongly positive correlation between liver flukes and 
cholangiocarcinoma in case-control studies (Parkin et al., 1991), malignant 
change in the biliary epithelium of Syrian hamsters has been shown after 
infection with O viverrini, especially if fed nitrosamines. These carcinogens 
are produced by bacteria in fish and other foods and are thought to act as a 
cofactor in cholangiocarcinogenesis (Khan et al., 2005). 
Fibropolycystic liver disease 
Congenital abnormalities of the biliary tree associated with Caroli’s disease, 
congenital hepatic fibrosis, and cystic dilatations of the bile ducts 
(choledochal cysts) carry a 15% risk of malignant change after the second 
decade, at an average age of 34 years. The overall incidence of 
cholangiocarcinoma in patients with untreated cysts is up to 28% (Lipsett et 
al., 1994, Scott et al., 1980). The mechanism of carcinogenesis is unclear, 
but could be related to biliary stasis, reflux of pancreatic juice causing chronic 
inflammation, activation of bile acids and deconjugation of carcinogens 
(Ohtsuka et al., 2001). Benign lesions like bile duct adenomas and biliary 
papillomatosis are also associated with the development of 
cholangiocarcinoma. Bile salt transporter protein polymorphisms in BSEP, 
FIC1, and MDR3 genes can lead to unstable bile content and to 
deconjugation of xenobiotics, previously conjugated in the liver (Jacquemin, 
2001, van Mil et al., 2001). In the presence of congenital bile duct 
abnormalities, this process can lead to the development of 
cholangiocarcinoma at an early stage in life. It is possible that individuals 
who are heterozygous for bile salt transporter polymorphisms have an 
increased predisposition to cholangiocarcinoma as adults, after exposure to 
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cofactors that result in chronic inflammation in the biliary tree (Khan et al., 
2005). 
Intra-hepatic biliary stones 
Intra-hepatic biliary stone is rare in the west, but relatively common in parts 
of Asia, and is associated with intra-hepatic cholangiocarcinoma which are 
usually peripheral in anatomical location (Shaib and El-Serag, 2004). Up to 
10% of patients with hepatolithiasis develop cholangiocarcinoma (Kubo et al., 
1995). In Taiwan, up to 70% of patients with cholangiocarcinoma undergoing 
resection have intra-hepatic biliary stones, and in Japan this figure is 6–18% 
(Okuda et al., 2002). The mechanism or carcinogenesis is thought to be bile 
stasis, predisposing to recurrent bacterial infections and subsequent 
inflammation, a potential cofactor for development of cholangiocarcinoma. 
Chemical carcinogen exposure 
Several chemical carcinogens have been associated with 
cholangiocarcinoma. Pro-mutagenic DNA adducts have been identified in 
cholangiocarcinoma tissue, indicating exposure to DNA-damaging agents 
(Khan et al., 2003). Thorotrast, a radiological contrast agent in use till 1960s 
and banned for its carcinogenic properties, has been strongly associated with 
the development of cholangiocarcinoma many years after exposure, 
increasing the risk to 300 times that of the general population (Sahani et al., 
2003, Shaib and El-Serag, 2004). Associations have also been made with 
exposure to by-products from the rubber and chemical industries, including 
dioxins and nitrosamines (Hardell et al., 1984), as well as with alcohol and 
smoking (Bergquist et al., 1998, Chalasani et al., 2000), but results have 
been conflicting and no firm conclusions have been established. 
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Viral hepatitis 
Cirrhosis has also been associated with cholangiocarcinoma (Shaib et al., 
2005, Sorensen et al., 1998). A cohort study of over 11,000 patients with 
cirrhosis, followed up over 6 years, showed a 10-fold risk compared with the 
general population (Sorensen et al., 1998). More specifically, hepatitis B and 
C viruses have been linked to the cancer. A case-control study from Korea 
reported that 12·5% of patients with cholangiocarcinoma tested positive for 
hepatitis C virus and 13·8% for hepatitis B virus surface antigen (HBsAg), 
compared with 3·5% and 2·3% of controls (Shin et al., 1996). In a second 
case-control study from Italy, 23% of patients with cholangiocarcinoma were 
positive for antihepatitis C virus and 11·5% were HbsAg-positive compared 
with 6% and 5·5% of controls, respectively (Donato et al., 2001). A 
prospective controlled study from Japan reported the risk of developing 
cholangiocarcinoma in patients with cirrhosis related to hepatitis C virus as 
3·5% at 10 years, 1000 times greater than in the general population 
(Kobayashi et al., 2000). Hepatitis C virus is an established risk factor for 
hepatocellular carcinoma and both hepatocytes and cholangiocytes have the 
same progenitor cell, supporting a role for the virus in carcinogenesis of both 
types of cancer. Furthermore, RNA from hepatitis C virus has been identified 
in cholangiocarcinoma tissue. A case-controlled study of risk factors for intra-
hepatic cholangiocarcinoma from the United States showed adjusted odds 
ratios of 6·1 for hepatitis C virus, and 5·9 for HIV infection. Diabetes was also 
prevalent in intra-hepatic tumours (adjusted odds ratio 2·0), but pathogenic 
mechanisms are unclear (Shaib et al., 2005). 
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Biliary-enteric bypass procedures 
In patients with biliary-enteric drainage procedures, reflux of intestinal 
contents into the biliary tree can occur and cause cholangitis.  It will be 
reasonable to expect that recurrent cholangitis may lead to biliary 
carcinogenesis on long-term follow up. Tocchi et al reviewed more than 1000 
patients undergoing three different procedures for biliary-enteric anastomosis 
(transduodenal sphincteroplasty, choledochoduodenostomy and 
hepaticojejunostomy) between 1967 and 1997 with a mean follow up of 
129.6 months. The overall incidence of bile duct carcinoma was 5.5% with 
the maximum incidence being in the group undergoing 
choledochoduodenostomy (7.6%). Cholangitis was an independent factor 
affecting the incidence of cholangiocarcinoma (Tocchi et al., 2001). A list of 
known risk factors is given in Table 1.3 below. 
 
 
 Age >65 years 
 Primary sclerosing cholangitis 
 Liver fluke infestation (i.e. Opisthorchis viverrini)  
 Choledochal cyst 
 Caroli’s disease 
 Bile duct adenoma and biliary papillomatosis 
 Hepatolithiasis 
 Viral hepatitis and cirrhosis 
 Chemical carcinogens (i.e. thorotrast) 
 Surgical biliary-enteric anastomosis 
 
Table 1.3: Risk factors for cholangiocarcinoma 
 
Gallbladder carcinoma 
Gallbladder carcinoma has been linked to several risk factors although a 
direct causative role has not been established with most of them. 
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Cholelithiasis 
The frequency of gallstones in the general population of the USA, as 
evidenced by the Framingham study, is 11% (Hart et al., 1971). The reported 
incidence of the association of gallstones in different series ranges from 40% 
to 100% (Adson, 1973, Chao and Greager, 1991, Hart et al., 1972, 
McLaughlin, 1964, Piehler and Crichlow, 1978, Shukla et al., 1985). 
Carcinoma of the gallbladder is extremely rare in the Bantu population, which 
is rarely affected by cholelithiasis (Pandey, 2003). There is a high incidence 
among Southwestern American Indians; symptomatic cholelithiasis has also 
been found to occur two to three times more frequently and at an earlier age 
in this population than in Caucasians (Reichenbach, 1967). Twenty-five per 
cent of carcinoma, however, occurs without documented cholelithiasis 
(Piehler and Crichlow, 1978). Kijima et al. (1989) suggested that chronic 
trauma and inflammation of the gallbladder mucosa, caused by the presence 
of gallstones, might induce epithelial dysplasia, which may predispose to 
carcinoma (Kijima et al., 1989, Piehler and Crichlow, 1978). However, if this 
hypothesis is true, one should see a higher incidence of squamous 
carcinoma rather then adenocarcinoma as malignant transformation in 
dysplasia gives rise to squamous carcinoma as seen at various other sites 
such as the cervix, the oral cavity and the oesophagus. The size of calculi 
was found to correlate with the probability of developing gallbladder 
carcinoma (Diehl, 1983). Comfort et al. (1948) followed silent gallstones for 
10–25 years; less than 1% of patients developed carcinoma (Comfort et al., 
1948). In another prospective randomized trial, 123 patients with gallstones 
were followed for more than 1000 person years; none of the patients 
 35 
developed carcinoma (Gracie and Ransohoff, 1982). The clinical data do not 
establish a causative role for the gallstones, although the association is 
frequent enough to suggest a common antecedent or at least a facilitative 
role. 
Racial and ethnic factors 
There is a marked geographical difference in the distribution of carcinoma of 
the gallbladder. The observation of a high prevalence of carcinoma of the 
gallbladder in certain population groups led to speculation about the possible 
role of racial and ethnic factors in carcinogenesis. Sievers and Marquis 
(1962) found carcinoma of the gallbladder to be the second most common 
disease of the gastrointestinal tract in American Indians (Sievers and 
Marquis, 1962). Richenbach (1967) reported a six times higher incidence in 
Southwest American Indians than in the non-Indian population 
(Reichenbach, 1967). Rudolph et al. (1970) found carcinoma in 4.5–6.0% of 
American Indians undergoing cholecystectomies (Rudolph et al., 1970). 
Krain (1972) reported a high incidence of carcinoma of the gallbladder in 
Japanese people and Hart et al. (1972)  found an incidence of 2.7/100 000 
among the Israeli population; a high incidence was also found in European 
born women who later migrated to Israel (Hart et al., 1972, Krain, 1972). 
Klein and Finck (1972) found carcinoma of the gallbladder to be two times 
more frequent in the Mexican population of Southwest America (Klein and 
Finck, 1972). Shukla et al. (1985) reported an incidence of 0.3% of total 
hospital admissions in the Varanasi region of India (Shukla et al., 1985). 
Klein and Finck (1972) reported abnormal hepatic bile with a low ratio of bile 
acid and lecithin to cholesterol among Southwest American Indians both with 
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and without gallstones (Klein and Finck, 1972). Davion et al. (1989) reported 
racial differences in gallbladder motor functions among North American 
Indians and black Africans and suggested a possible role in cholelithiasis 
(Davion et al., 1989). Social and economic factors affecting dietary intake 
and environmental factors may also be responsible for this wide geographical 
variation observed in various groups with carcinoma of the gallbladder. 
However, this hypothesis needs to be tested in case–control and cohort 
studies. 
Familial occurrence 
The greater risk of developing the same cancer as a first degree relative, for 
breast, stomach, colon and prostate cancers is well established (Lynch, 
1969). Patients suffering from gallbladder carcinoma are known to develop a 
second malignancy in 15% of cases and a family history of cancer of another 
organ is present in 33% of cases (Perpetuo et al., 1978). The first report of 
familial occurrence of carcinoma of the gallbladder came from two families of 
Hispanic New Mexicans (Devor and Buechley, 1980). The only other report is 
from Brazil (Trajber et al., 1982). Although three cases of familial linkage 
have been reported to date, the exact role of genetic factors in the causation 
of gallbladder carcinoma is still not clear. 
Biliary tract anomalies 
The anomalous junction of the pancreaticobiliary duct system is a congenital 
defect, characterized by the union of a common bile duct outside the 
duodenal wall. Because of the action of the sphincter muscle, this does not 
affect the union functionally but it is associated with various complications 
such as cholangitis, gallstones, biliary tract cancers, pancreatitis and 
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pancreaticolithiasis (Committee of Diagnostic Criteria of the Japanese Study 
Group on Pancreaticobiliary Maljunction, 1991). Attention has recently been 
focused on the high incidence of cancer of the biliary tract in patients with 
this anomaly (Aoki et al., 1987, Kimura et al., 1985, Kinoshita et al., 1984, 
Nagata et al., 1986). The incidence of malignant changes has been reported 
to be 15–40% (Aoki et al., 1987, Kimura et al., 1985, Ohta et al., 1990). 
There is an especially high incidence of cancer of the gallbladder in the 
anomalous junction without bile duct dilatation (Ohta et al., 1990). The 
incidence of gallstones in patients with carcinoma of the gallbladder 
associated with the anomalous junction is very low (Aoki et al., 1987). The 
reflux of pancreatic juice into the gallbladder with consequent chronic 
cholecystitis with intestinal metaplasia, a precancerous condition leading to 
differentiated carcinoma, has been implicated and the concentration of bile 
within the gallbladder of these patients may also promote gallbladder 
carcinogenesis (Nagata et al., 1985, Komi et al., 1982). 
Chronic cholecystitis 
The observation by Piehler and Crichlow (1978) that 40–50% of patients with 
gallbladder carcinoma had a history of antecedent chronic cholecystitis led to 
the theory that chronic cholecystitis per se is a causative factor in 
pathogenesis. However, the frequent association of stones precludes 
isolation of the effect of inflammation (Piehler and Crichlow, 1978). 
Calcification of the wall of the gallbladder, the so-called porcelain gallbladder, 
is believed to be an end stage of chronic cholecystitis. The incidence of 
carcinoma in calcified gallbladder is 12.5–61%, indicating that this is a high-
risk group for developing carcinoma (Polk, 1966, Berk et al., 1973). 
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Xanthogranulomatous cholecystitis 
This refers to lipids accompanying bile pigments and entering the connective 
tissue of the gallbladder wall, resulting in an inflammatory process. This lipid 
is sometimes oxidized to a coloured chromolipid and the condition is called 
ceroid granuloma (Amazon and Rywlin, 1980), ceroid-like histiocytic 
granuloma (Takahashi et al., 1976) or fibroxanthogranulomatous 
inflammation (Mehrotra and Bhatnagar, 1982). These terms now have been 
replaced by xanthogranulomatous cholecystitis (Mehrotra and Bhatnagar, 
1982), a descriptive term first used by McCoy et al. (McCoy et al., 1976). The 
incidence of xanthogranulomatous cholecystitis ranges from 0.7% in Illinois, 
USA (Reyes et al., 1981) to 1.8% in Sheffield, UK (Benbow, 1990) with 
Japan having an intermediate rate of 1.2% among routine cholecystectomy 
specimens (Takahashi et al., 1976), although recent studies from Japan 
claim an incidence of 9% (Hanada et al., 1987). Not only does 
xanthogranulomatous cholecystitis mimic carcinoma in various ways, but 
there appears to be a possible association between the two. Gallbladder 
carcinoma was over-represented in a series of patients with 
xanthogranulomatous cholecystitis from Sheffield and the condition was 
more frequent than expected in series from Manchester, UK (Benbow, 1990, 
Houston et al., 1994). The reason for this association is not clear. However, it 
may simply be that xanthogranulomatous cholecystitis and adenocarcinoma 
are both complications of cholelithiasis and cholecystitis of a particular 
duration or degree, or it could be due to the tissue disruption by the 
carcinoma facilitating the entry of bile into the stroma (Benbow, 1989). The 
association, nevertheless, is important as both lesions are represented in the 
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same specimen and there is always a possibility of overlooking the 
carcinoma altogether (Benbow and Taylor, 1988). 
Bacterial infections 
The role of anaerobic and aerobic bacteria in biliary tract disease is well 
investigated (Flemma et al., 1967). Among aerobes, Escherichia coli, other 
coliform bacilli and enterococci are frequently encountered. Clostridium 
perfringens is the most common anaerobic organism along with anaerobic 
gram-positive cocci, B. fragilis, lactobacilli and actinomycetes in a small 
number of cases (Shimada et al., 1977). Dawson and Isselbacher (1960) 
demonstrated the toxicity of unconjugated bile acids and reported that 
unconjugated deoxycholate at a concentration of 5 X10–3M causes 
dissolution of mucous membranes with loss of villi (Dawson and Isselbacher, 
1960). Anaerobic bacteria deconjugate bile acids very effectively whereas 
aerobic bacteria, except Streptococcus feacalis and few other species, are 
inactive suggesting a possible role of bacterial deconjugation in tumor 
genesis (Shimada et al., 1969). Lowenfels (1978) proposed that in patients 
with gallstones the secondary bacterial infection releases cancer initiators or 
promoters from bile (Lowenfels, 1978). Kinoshita and Gelboin (1978) 
reported the formation of highly reactive intermediates during glucuronidase 
action of biliary glucuronidase, which bind to DNA and so are potentially 
carcinogenic (Kinoshita and Gelboin, 1978). Shukla et al. (1993) reported an 
increased bacterial degradation of primary to secondary bile acids, which are 
potent tumour initiators and promoters (Shukla et al., 1993). They suggested 
this to be a possible mechanism of carcinogenesis in patients with gallstones 
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Typhoid carriers 
The production of tumour promoters and initiators by bacterial degradation of 
bile in the gastrointestinal tract is well established (Hill and Cook, 1986). An 
association of the chronic typhoid carrier state and carcinoma of the 
gallbladder was first reported by (Axelrod et al., 1971). (Welton et al., 
1979)observed an excess of cancer of the hepatobiliary system in typhoid 
carriers; this was later confirmed by other studies (el-Zayadi et al., 1991, 
Mellemgaard and Gaarslev, 1988). Caygill et al. (1994) studied cancer 
mortality in people infected during the Aberdeen typhoid outbreak in 1964, in 
those who did not become carriers and in the carriers registered with the 
communicable disease unit in Scotland. They found increased mortality from 
cancers in the chronic typhoid carriers concluding that progression to chronic 
carrier states and not typhoid infection per se carries the excess cancer risk; 
and in the hepatobiliary system the main risk appears to be in the 
gallbladder. Their results suggested a lifetime risk of developing gallbladder 
cancer in 6% of the typhoid carriers (Caygill et al., 1994). An increased 
carrier rate among patients with gallbladder cancer has also been reported 
by Singh et al. and Shukla et al. from India (Singh et al., 1996). 
Ulcerative colitis 
The association between ulcerative colitis and biliary tract diseases is well 
known (Converse et al., 1971). Carcinoma of the extra-hepatic biliary tract is 
5–10 times more frequent in patients with ulcerative colitis than in the general 
population (Ritchie et al., 1974, Converse et al., 1971). The first report of a 
biliary tract tumour and ulcerative colitis occurring in the same patient was 
made by Parker and Kendall (Parker and Kendall, 1954). The majority of 
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these carcinomas are of the bile duct; eight patients with carcinoma of the 
gallbladder have been reported (Warren et al., 1968, Babb et al., 1970, 
Converse et al., 1971, Morowitz et al., 1971, Ritchie et al., 1974, Herzog and 
Goldblum, 1996). The cause of these malignant lesions is not known. They 
frequently occur without pre-existing hepatobiliary disease and have been 
known to occur up to 53 years after total colectomy. Carcinoma of the 
gallbladder in association with ulcerative colitis therefore seems to have a 
different pathogenesis. A causative role of altered bile metabolism is only 
speculative (Dawson and Isselbacher, 1960, Piehler and Crichlow, 1978). 
Reproductive and hormonal factors The overall increased frequency of 
gallbladder carcinoma in women and bile duct cancer in men suggests a 
possible role for hormonal factors (Silk et al., 1989). The role of women’s 
hormones in the formation of cholesterol gallstones is well established 
(Bennion and Grundy, 1978). A case–control study within the framework of a 
programme for studying risk factors in relation to cancer (Surveillance on 
Environmental Aspects in Relation to Cancer in Humans (SEARCH) 
programme) established by the International Agency for Research on Cancer 
((IARC)) has shown that a younger age at menarche, an early age at first 
pregnancy, a higher number of pregnancies and prolonged fertility may 
enhance the risk of extrahepatic biliary tract malignancies (Plesko et al., 
1985, Lambe et al., 1993, Moerman et al., 1994, Zatonski et al., 1997). The 
exact role of women’s hormones is not yet clear, however, overall increased 
exposure to endogenous oestrogens and progesterone continues to be a 
high risk factor (Yen et al., 1987). 
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Dietary and life-style factors 
The role of dietary factors in gallbladder cancer has been evaluated 
previously in several studies (Strom et al., 1995, Moerman et al., 1995, 
Moerman et al., 1997, Zatonski et al., 1992, Zatonski et al., 1997, Pandey 
and Shukla, 2002). An increased risk has been observed with obesity and a 
diet high in cholesterol, protein, carbohydrate and meat, while a diet high in 
fibre, vitamins C and E, fruits and vegetables appears to lower the risk. Life-
style factors such as smoking and drinking alcohol have been found to be 
associated with obesity, gallstones and the risk of developing gallbladder and 
extra-hepatic bile duct cancers in earlier case–control studies (Moerman et 
al., 1997, Tseng et al., 1999). However, due to small numbers, it is difficult to 
derive any possible association. It appears to indirectly increase the risk, 
probably by increasing the incidence of gallstones and obesity. Benign 
neoplasms of the gallbladder have been identified in 0.15–8.5% of resected 
gallbladders (Piehler and Crichlow, 1978). The increased use of 
ultrasonography as the investigation of choice in patients with biliary 
symptoms has led to the increased detection of benign neoplasms, which 
until the last decade were considered to be of little significance and unlikely 
to undergo malignant change (Sawyer, 1970, Aldridge and Bismuth, 1990). 
Christenson and Ishak reviewed and classified 180 gallbladder tumours and 
found three cases of carcinoma in situ associated with non-papillary 
adenoma (Christensen and Ishak, 1970). Evidence for an adenoma–
adenocarcinoma sequence comes from the study by Kozuka et al., who 
reviewed 1605 gallbladders and found seven adenoma with malignant 
changes and 79 invasive carcinomas; all the benign adenomas were less 
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than 12mm in diameter. All adenomas showing malignant changes were over 
12mm and most invasive carcinomas were over 30 mm. There was a 
preponderance among women for both adenomas and invasive carcinomas 
(Kozuka et al., 1982). The need to define the precise relationship between 
the benign gallbladder neoplasm and the carcinoma was emphasized by 
Aldridge and Bismuth (Aldridge and Bismuth, 1990). Only five cases of 
carcinoma of the gallbladder developing in adenomyomatosis have been 
reported in the literature (Kawarada et al., 1986, Paraf et al., 1987, Katoh et 
al., 1988, Aldridge et al., 1991), despite the fact that adenomyomatosis 
constitutes 40% of benign gallbladder neoplasms. From the work undertaken 
by various authors there appears to be an increased risk of malignant 
transformation in some benign lesions like adenomas and it could be one of 
the mechanisms of carcinogenesis.  
Carcinogens 
The chemical similarity of the carcinogen methyl cholanthrene to naturally 
occurring bile acids has led to speculation that carcinoma of the gallbladder 
could be caused by such chemical transformation, in vivo. Methyl 
cholanthrene has not been identified as such in bile of patents with 
carcinoma (Gradisar and Kelly, 1970, Alonso de Ruiz et al., 1982, Klamer 
and Max, 1983, Chao and Greager, 1991). Fortner and others were able to 
induce cancer by implanting pellets of chemicals into gallbladders of cats and 
dogs (Fortner and Leffall, 1961, Fortner, 1955a, Fortner, 1955b). Simmers 
and Podolak failed to produce carcinoma by inserting methyl cholanthrene 
pellets in gallbladders of guinea pigs, establishing a significant species 
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difference (Simmers and Podolak, 1963). The introduction of foreign bodies 
into the gallbladder is also known to cause carcinogenesis. Petrov and 
Krotkina  induced carcinoma by inserting glass rods into guinea pig 
gallbladders (Petrov and Krotkina, 1947). Feeding numerous other chemicals 
including O-aminoazotoluene and various nitrosamines has induced 
carcinoma of the gallbladder (Erturk et al., 1970, Enomoto et al., 1974, Kelly 
and Chamberlain, 1982, Klamer and Max, 1983). Cryer and Kissane linked 
biliary tract cancer to benzidine, 3,3-dichloro benzidine and M-
toluenediamine. Kowalewski and Todd  reviewed the probable multifactorial 
aetiology of this disease by inserting cholesterol pellets into the gallbladders 
of hamsters and later feeding them dimethyl nitrosamine; 67% developed 
cancer compare to 6% of control animals fed on carcinogen only 
(Kowalewski and Todd, 1971). 
Secondary bile acids 
Interest in the hypothesis that bile acids are possible precursors of 
carcinogenic aromatic hydrocarbons has now faded. However, there is a 
large body of evidence to suggest that bile acids are tumour promoters and 
co-mutagens (Reddy et al., 1976, Wilpart, 1991), can cause dysplastic 
changes in colonic mucosa (Wargovich et al., 1983, Castleden et al., 1989, 
Rafter and Branting, 1991) and are strongly implicated as tumour promoters 
in colon carcinogenesis (Hill, 1991, Hill, 1983) and in gastric cancer 
(Houghton et al., 1986). Bile acids are also reported to influence the growth 
and morphology of cultured human fibroblasts (Trias et al., 1977) and to 
promote hepatoma formation in rats. Shukla et al. reported higher levels of 
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secondary biliary bile acids in patients with carcinoma of the gallbladder, 
suggesting a possible role in gallbladder carcinogenesis (Shukla et al., 
1993). Pandey et al. demonstrated increased degradation of primary to 
secondary bile acids by bacterial degradation (Pandey et al., 1995).  
Free radicals  
Free radical mechanisms are increasingly being implicated in almost all 
disease states (Del Maestro et al., 1980, Bulkley, 1983, Halliwell and 
Gutteridge, 1984, Halliwell, 1989, Reilly and Bulkley, 1990, Sinclair et al., 
1990). Their relationship to neoplastic transformation in particular has 
attracted much attention (Breimer, 1988). Biological oxidation involves the 
generation of electrons from mitochondria and if improperly managed by 
cellular antioxidants is liable to induce the generation of reactive oxygen 
species (ROS). The ROS may cause oxidant damage to enzymes, nucleic 
acids, cytosolic and membrane proteins and the cellular lipids largely present 
in cell membranes. Carbon tetrachloride and halogenoalkanes are the most 
common chemical pollutants produced by industries and automobiles. These 
can be absorbed through the skin or ingested through water and they 
produce hepatotoxicity in virtually all species. The hepatotoxicity of 
halogenoalkanes involves reductive dehalogenation by cytochrome p450, of 
the hepatic microsomal mixed function oxygenase system to form 
trichloromethyl (CCl3) and trichloromethylperoxy (CCl3O2) radicals (Brattin et 
al., 1985, Rosen and Rauckman, 1982). Although a consensus on direct 
proof for the generation of carbon tetrachloride free radicals has not yet been 
reached, indirect evidence for their microsomal formation is overwhelming 
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(Rosen and Rauckman, 1982). Carcinogenesis is thought to occur in two 
stages, first, the initiation stage, during which a physical, chemical or 
biological agent directly causes an irreversible alteration in the molecular 
structure of DNA and second, the promotion stage, during which the 
expression of genes that regulate cell growth and differentiation is altered. 
Experimental studies strongly suggest that free radicals are active in both the 
initiation and promotion stages of cancer, making it an important aetiological 
agent in carcinogenesis (Floyd, 1990). 
Lipid peroxidation products 
Polyunsaturated fatty acids are particularly vulnerable to free radical attack. 
The oxidative damage is termed lipid peroxidation and causes a reduction in 
membrane fluidity and permeability besides producing highly genotoxic and 
tumourigenic aldehydic lipid peroxidation products (Pandey et al., 1995, 
Shukla et al., 1994, Rosen and Rauckman, 1982). Linolenic acid (C18:2) and 
arachidonic acid (C20:4) contain a number of methylene-interrupted double 
bonds, which are particularly prone to hydrogen abstraction. This process 
can be autocatalytic. However, it can be halted by the action of free radical 
scavenger molecules (Chopra et al., 1989, Kirkpatrick and Lauer, 1986, 
Gutteridge et al., 1979). The NADPH-cytochrome p450 electron transport 
chain present in liver microsomes acts as an electron donor and promotes 
the generation of free radicals, thereby initiating lipid peroxidation (Slater and 
Sawyer, 1971b, Slater and Sawyer, 1971a). Of the various lipid peroxidation 
products, 4-hydroxynonenal (HNE) has a high neoplastic potential (Benedetti 
et al., 1980, Esterbauer et al., 1982, Esterbauer and Zollner, 1989, 
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Esterbauer et al., 1985). Shukla et al. have shown an increase in the 
concentration of HNE in gallbladder bile of patients with carcinoma of the 
gallbladder (Shukla et al., 1994). A further significant decrease in the 
concentration of polyunsaturated fatty acids (linolenic and arachidonic acid) 
in patients with gallstones has been demonstrated leading to speculation that 
increased lipid peroxidation along with non-functioning of the gallbladder, 
which causes HNE to be retained in the gallbladder for a long duration and in 
high quantities, may be responsible for the malignant conversion (Pandey 
and Shukla, 2000, Pandey et al., 1995, Pandey et al., 2000). 
Molecular and genetic factors  
In the past decade there has been an increased interest in identifying 
molecular and genetic factors responsible for cancer initiation, progression, 
proliferation and metastasis. Several factors have been studied in gallbladder 
cancer. Of these, much work pertains to the tumour suppressor gene p53 
and K-ras oncogene. The p53 gene is one of the most frequently mutated 
genes in many cancers, including gallbladder cancer, where it appears to be 
an early event (Billo et al., 2000). These mutations are commonly observed 
on axons 5, 6, 7 and 8 (Fujii et al., 1996, Jonas et al., 1997). p53 mutations 
in gallbladder cancer have been demonstrated in carcinomas that arises in 
association with adenoma (along with APC gene mutations) and in those 
associated with pancratico-biliary malunion (Itoi et al., 1999, Itoi et al., 1996, 
Kanthan et al., 2000, Kim et al., 2001). The K-ras gene is one of the most 
commonly detected oncogenes in human cancers. K-ras gene mutations are 
commonly found in codon 12 in patients with gallbladder cancer (Hanada et 
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al., 1996). These mutations are also seen in tumours arising ab initio, in 
malignant transformation of premalignant lesions and in patients with 
pancreatico-biliary malformation (Hanada et al., 1999, Ajiki et al., 1996, 
Hanada et al., 1996, Iwase et al., 1997). Studies on allele-specific mutations 
and loss of heterozygosity (LOH) in gallbladder cancer have revealed LOH at 
the p53 locus in up to 90% of patients, at 19q (the site of the DCC gene) in 
31%, at 5q (the APC gene) in 22% and at 13q (the Rb gene) in 22% of cases 
(Wistuba et al., 1995). Using micro-satellite markers a high frequency of 
allelic loss has been demonstrated at 2p (82%), 4p (50%), 4q (50%), 8q 
(60%), 9q (50%), 10p (50%), 14p (60%), 14q (50%), 16p (60%), 19p (50%), 
21p (50%) and Xp (67%) (Nakayama et al., 2001). However, most of these 
studies are retrospective on archival tissue with small samples and hence no 
significant conclusions can be drawn from these studies. 
The aetiology of gallbladder cancer remains far from clear and none of the 
above risk factors has been demonstrated to have a direct cause and effect 
relationship. However, it is fair to say that the disease is probably multi-
factorial and more research is continuing to look at this difficult disease. 
Pancreatic & periampullary cancer 
The causes of pancreatic and periampullary cancer are not known. However, 
a variety of risk factors have been identified.  
Smoking 
The risk factor most consistently identified is cigarette smoking, which may 
account for approximately 25–30% of cases of pancreatic adenocarcinoma. 
Relative risks for pancreatic cancer generally ranged between 1.5 and 3 for 
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current smokers versus non-smokers (Silverman et al., 1994). A dose-
response relationship has been reported by some studies with increasing 
dose and duration of smoking (Lin et al., 2002).  
Familial pancreatic cancer 
Five to ten percent of pancreatic cancers are hereditary in nature. Three to 
five fold higher risk of developing pancreatic cancer is reported in individuals 
with a close relative with the same disease. No single pancreatic cancer 
gene has been identified but a number of inherited cancer syndromes have 
been associated with higher number of pancreatic cancer. These syndromes 
include familial breast cancer (BRCA2 mutation), familial atypical multiple 
mole melanoma syndrome (FAMMM), hereditary pancreatitis, hereditary non-
polyposis colorectal cancer (HNPCC) and Peutz-Jeghers Syndrome (Lal et 
al., 2000, Kern et al., 2002). 
Other factors  
Various other factors, including diet (high fat and protein, low fruit and 
vegetable intake), coffee consumption, alcohol, occupation, and the effects of 
other diseases such as diabetes mellitus, pernicious anaemia, chronic 
pancreatitis, cholelithiasis, and previous gastric surgery, have also been 
studied in detail. Of these, only in chronic pancreatitis and adult onset 
diabetes of less than two years’ duration does there seem to be clear 
evidence of an increased risk of pancreatic cancer (Everhart and Wright, 
1995, Lowenfels et al., 1993). Chronic pancreatitis is associated with an 
increased risk of cancer of the order of 5–15-fold. Periampullary cancers can 
be broadly considered as those tumours arising out of or within 2 cm of the 
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papilla of Vater and include ampullary, pancreatic, bile duct, and duodenal 
cancer. There is a high incidence of these tumours in patients with familial 
adenomatous polyposis (FAP). The median interval between colectomy for 
FAP and the development of upper gastrointestinal cancer is 22 years and 
cancer is often preceded by ampullary or duodenal adenoma or arises in an 
adenoma.  
Molecular pathogenesis of pancreatobiliary malignancy 
A number of mutations in oncogenes and tumour suppressor genes have 
been identified in cholangiocarcinoma, suggesting the cancer may arise 
secondary to cellular damage and consequent DNA injury (Berthiaume and 
Wands, 2004). Several studies have shown abnormal expression of the K-
ras oncogene in 21–100% of cases and the p53 tumour suppressor gene in 
up to 37% of archival specimens in the largest studies (Nehls et al., 2004). 
These genetic alterations are associated with a more aggressive phenotype 
in this cancer (Isa et al., 2002, Nehls et al., 2004). K-ras and p53 mutations 
have also been identified in bile and pancreatic juice of affected patients 
(Nehls et al., 2004, Wang et al., 2002). Neither K-ras nor p53 mutational 
analysis have been shown to be superior to conventional cytopathology in 
the diagnosis of pancreaticobiliary tumours, but combined analysis of both 
can increase sensitivity in tissue biopsy and bile specimens (Itoi et al., 1999, 
Nehls et al., 2004, Wang et al., 2002). Increased expression of c-met and c-
erbB-2 proto-oncogenes has been shown and they have been suggested to 
participate in the metastatic transformation of intrahepatic tumour (Aishima et 
al., 2002). Over expression of the protooncogene Bcl-2 has been reported to 
reduce apoptosis in cholangiocarcinoma cell-lines (Harnois et al., 1997). 
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Although human cholangiocarcinoma does not express Bcl-2, other 
antiapoptotic proteins, mcl-1 and Bcl-xl, are expressed. Point mutations 
leading to promotor methylation of cell cycle regulators p16INK4a and 
p14ARF have also been identified in cholangiocarcinoma related to primary 
sclerosing cholangitis (Khan et al., 2005). Other potential molecular markers 
for biliary malignancy are currently under investigation. These include growth 
factors and the occurrence of DNA aneuploidy, nuclear morphometry, and 
loss of heterozygosity of microsatellite markers (Itoi et al., 1999).  
Mechanism of carcinogenesis  
In recent years considerable progress has been made in understanding the 
pathogenesis of cholangiocarcinoma. Development of cholangiocarcinoma is 
probably a multi-step process involving the interaction between 
environmental and genetic factors. Malignant transformation of biliary 
epithelium occurs in an environment of chronic biliary inflammation and most 
of the environmental risk factors for cholangiocarcinoma cause chronic biliary 
irritation leading to inflammation. Several potential genetic changes and their 
interaction with environmental factors are summarised in Figure 1.6 
(Berthiaume and Wands, 2004, Khan et al., 2005). In a recent review, Khan 
et al proposed that genetic polymorphisms in the cytochrome P450 enzymes 
or in the bile salt transport proteins could lead to alterations in the efficiency 
with which environmental toxins (xenobiotics) are handled by the liver (Khan 
et al., 2005). The development of cholangiocarcinoma probably needs a 
“second hit” to activate such xenobiotics and to expose the cholangiocytes to 
damage. Such secondary hits include chronic inflammation, viral hepatitis, 
worm infestation and recurrent cholangitis. 
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Figure 1.6: Proposed model for carcinogenesis in cholangiocarcinoma showing 
interaction between environmental factors and host genetics (Khan et al., 2005). 
 
Environmental pollution, heavy metals and pancreato-biliary 
malignancy 
Metals are natural elements that have been extracted from the earth and 
used for human industry and products for thousands of years but they also 
form a major category of environmental pollutants. Metals are notable for 
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their wide environmental dispersion, their tendency to accumulate in selected 
tissues of the human body and their potential to be toxic at a very minor level 
of exposure. Some metals, such as copper or iron, are essential to life and 
play a very important role in the functioning of critical enzyme systems. Other 
metals are xenobiotics, i.e, they have no useful role in human biology and 
worse are the metals like lead or mercury which may be toxic at even trace 
exposure. One reflection of the importance of metals relative to other 
potential environmental hazards is their ranking by the U.S. Agency for Toxic 
Substances and Disease Registry (ATSDR), which lists all hazards present 
in toxic waste sites according to their prevalence and the severity of their 
toxicity. The first, second, third and sixth hazards on the list are heavy 
metals: lead, mercury, arsenic and cadmium, respectively.  
Exposure to metals can occur through various routes. They van be inhaled 
as dust or fumes or as vapour.  They can also be ingested through food or 
drink as contaminants. The amount that is actually absorbed from respiratory 
or digestive tract is variable and depends on the chemical form of the metal 
and the age and physical status of the individual. Once absorbed, metals are 
distributed in tissues and organs excreted primarily through kidneys and 
digestive tract, but they tend to persist in some storage sites, like the liver, 
bones and the kidneys, for several years. 
Acute and high dose toxicity to the metals usually involves the brain or the 
kidneys and produces generalized symptoms to start with, which makes their 
diagnosis quite difficult. More worrying is the long term low dose exposure, 
which may result in chronic illnesses like hypertension with exposure to lead 
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and renal impairment with cadmium and the potential of some heavy metals 
to be carcinogenic e.g. arsenic and cadmium. 
A wide variety of metals including copper, lead, cadmium, iron, molybdenum, 
chromium, silicon and silver is reported in increasingly high quantities in 
people with cancer (Gupta et al., 1993, Delves et al., 1973). Inutsuka and 
Araki reported an elevated copper/zinc ratio in malignancy, including one 
case of carcinoma of the gallbladder and a further increase in advanced 
disease especially with liver metastasis (Inutsuka and Araki, 1978). There 
are reports of high cadmium concentration in renal and hepatic tissues of 
patients with bronchogenic carcinoma. There are authors who attribute this 
cadmium toxicity to its role as an antimetabolite of zinc. Several authors 
reported in the past that cadmium is a potent uncoupler of oxidative 
phosphorylation in vitro and that defective respiration is characteristic of 
tumour cells (Balo and Banga, 1957, Bradley et al., 1956). High levels of 
heavy metals in the bile of patients with carcinoma of the gallbladder have 
been reported (Shukla et al., 1998b). Metallothioneins (MTs) are a group of 
closely related low-molecular-weight proteins with a high affinity for the 
metals of groups I and IIB of the periodic table (Mulder et al., 1992). High 
levels of endogenous MTs bound to copper are observed in mammalian liver 
during gestation and in the early postnatal period (Bremner et al., 1977). The 
exact role of MTs is not yet clear, however, it is thought to point towards 
intercellular storage of essential metals (Webb and Cain, 1982). MT 
synthesis can be induced by the injection of certain metals (Onosaka et al., 
1986). Increased MT expression has been demonstrated in patients with 
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carcinoma of the gallbladder compared to control patients and patients with 
cholecystitis (Shukla et al., 1998a). This suggests a possible role of heavy 
metal toxicity in gallbladder carcinogenesis and also as cadmium replaces 
copper from endogenous MT, the increased concentration of cadmium may 
give rise to an increased concentration of copper in the hepatic tissue and 
hence an altered copper/zinc ratio, as has been observed by various workers 
(Delves et al., 1973, Gupta et al., 1993).  
In a meta-analysis of environmental studies looking at occupational 
exposures and pancreatic cancer, Ojajärvi et al concluded that about 20-25% 
of pancreatic cancer are related to smoking and about 15-20% are due to 
occupational and environmental pollutants in a typical “western” population 
(Ojajarvi et al., 2000). Exposure to nickel and chromium compounds had a 
relation to development of pancreatic cancer. Recently, a lot of interest has 
been focused on association of cadmium with pancreatic cancer. The 
strongest suspicion of an association between cadmium exposure and 
pancreatic cancer has been reported in Louisiana in the United States (Blot 
et al., 1978, Lemus et al., 1996). Industrial activity along the Mississippi River 
has led to an accumulation of contaminants in southern Louisiana (Mielke et 
al., 2000). Seafood and rice are popular food items in the local diet. Both rice 
and fish harvested from cadmium-polluted areas may contain high levels of 
cadmium (Ikeda, 1992). A case–control study in Louisiana showed a 
significantly increased risk for pancreatic cancer associated with rice 
consumption among the local population, with a dose response relationship 
(Falk et al., 1988, Falk et al., 1990). A more recent study published looking at 
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a population in the East Nile delta region in Egypt shows a strong correlation 
between cadmium exposure and development of pancreatic cancer (Kriegel 
et al., 2006). Schwartz and Reis in 2000 introduced a cadmium hypothesis 
for development of pancreatic cancer (Schwartz and Reis, 2000). The four 
commonly recognized risk factors for pancreatic cancer were interpreted with 
their association to cadmium exposure as in the following table (Table 1.4). 
 
Risk factor Explanation by cadmium hypothesis 
Age Cadmium accumulates in the pancreas with age. 
Smoking 
Cadmium is a contaminant of cigarettes. The pancreas of 
smokers contains twice the amount of cadmium as the 
pancreas of nonsmokers 
Geography 
Increased rates in Louisiana are consistent with cadmium 
pollution. International mortality rates are positively correlated 
with dietary cadmium. 
Occupation 
Occupations with high exposure to cadmium show increased 
mortality from pancreatic cancer 
 
Table 1.4: Risk factors for pancreatic cancer and their interpretation by the cadmium 
hypothesis (Schwartz and Reis, 2000). 
 
The evidence from research in areas with high environmental exposure to 
heavy metals quite strongly favours a relation between environmental 
pollution and pancreatobiliary malignancy. However, very little 
epidemiological research has taken place in areas, which do not seem to 
have major problems with environmental heavy metal exposure. The 
incidence of pancreato-biliary malignancy is also increasing in such areas 
and, therefore, it will be interesting to see whether environmental factors 
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have a significant correlation with increased incidence of pancreatobiliary 
malignancy in these regions. 
An interesting study emerged from an area of high environmental pollution 
and high incidence of gallbladder cancer in the Northern Indian state of Uttar 
Pradesh. Shukla et al in a study published in 1998 demonstrated a relation 
between high level of heavy metals in the bile and gallbladder cancer. The 
study looked at a population in Northern India where there is significant 
environmental pollution with heavy metals. Bile samples from 38 patients 
with gallbladder cancer were compared with 58 patients with benign 
gallstones in a case control study (Figure 1.7).  
 
 
Figure 1.7: Cadmium, chromium and lead concentration in patients with gallstones 
and gallbladder cancer (Shukla et al., 1998b). 
 
 58 
The figure shows the mean biliary concentrations of cadmium, chromium and 
lead are significantly higher in patients with gallbladder cancer than those 
with gallstones. This indicates a possible relation between environmental 
exposure to these metals and development of biliary cancer, although a 
direct cause and effect relationship cannot be established.  
In the North-East of England, environmental pollution is not as much a 
problem as in Northern India. However, this part of the country has been 
traditionally an area of heavy industry including mining and shipbuilding. 
Although these traditional industries are no longer a major contributor to the 
local economy, this region still has pockets of heavy industry, including 
chemical industry, especially in the southern part of this region in Teesside. 
To investigate the possibility of local air pollution contributing to health 
problems, a study in 1998 by the Department of Epidemiology and Public 
Health, University of Newcastle, looked at different areas of Teesside 
according to proximity to industry and also compared it with the neighbouring 
metropolitan population in Sunderland. There was no significant difference in 
health problems, although there was a trend towards increased incidence of 
lung cancer amongst the population closer to industry, but this trend was not 
statistically significant (Bhopal et al., 1998). The same group studied the 
relation of lung cancer, proximity to industry and social deprivation in 
Teesside and found an increased incidence of lung cancer related mortality 
in women under 75 years of age living in close proximity to industry (Pless-
Mulloli et al., 1998). This group continued to work on the same theme in the 
North East of England and looked at the duration of exposure to 
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environmental pollution in populations living close to heavy industry and 
reported a modestly increased risk of lung cancer (Edwards et al., 2006). 
Similar projects looking at the possible relationship of biliary and pancreatic 
cancer with heavy metal exposure in this country have not been done. 
Investigations done abroad on areas of high environmental exposure to 
heavy metals provide interesting data for carrying out similar project in the 
UK (Kriegel et al., 2006, Shukla et al., 1998b).  
The present project was based on the model from India published by Shukla 
et al in 1998. This was a simple model where patients with gallbladder 
cancer had a sample of bile collected during surgery and different heavy 
metals levels in the bile were measured. Bile sample was also collected from 
a group of patients with benign gallstone disease and the levels of each 
heavy metal in these 2 groups were compared. However, the project in India 
was carried out in a region of heavy industrial pollution with obvious 
exposure to heavy metals for the population living in those areas. Although 
areas in the North-East of England have heavy industry, the degree of 
pollution is not as high as experienced in India. Epidemiological projects 
done locally in the North-East of England on environmental pollution and lung 
cancer supports similar project to look at the possible relation of heavy 
metals and pancreato-biliary malignancy (Bhopal et al., 1998). 
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2. Aim of the Study 
 
 
Cancer is a serious health problem, both in the UK and across the North-
East of England. There were 243,400 new cases of cancer in England in 
2006, of those 13,600 were in the North East. There were 7,500 cancer 
related deaths in the North-East of England in the same year. Between 2001 
to 2005, the incidence of all cancers in England (excluding non-melanoma 
skin cancers) was 380.0 per 100,000 population, and the incidence was 
411.6 per 100,000 in the North-East of England over the same period. The 
mortality rate for all cancers is also higher in the North East compared to 
England (214.8 compared to 187.7 per 100,000 population respectively). The 
five-year survival rate for all cancers is 48.4% across England compared to 
43.2% in the North East (North East Public Health Observatory, 
(www.nepho.org.uk). 
 
The above data highlights the need for improvement in cancer related 
services as well as cancer research in the North East of England. There has 
been a major move towards centralization of cancer services in this region in 
the past decade led by the Northern Cancer Network. Hepato-biliary and 
pancreatic cancer surgery has been centralized to the tertiary referral centre 
at Freeman Hospital, Newcastle upon Tyne. The present project was 
conducted in the Freeman Hospital and Department of Surgery and 
Department of Agriculture, University of Newcastle upon Tyne. Being the 
tertiary referral centre for the whole region, all patients with suspected 
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hepato-biliary and pancreatic cancers are referred to the Freeman Hospital 
and that helped in identifying and recruiting patients for the study. 
The main aims of the study were as follows: 
1. Identify and recruit patients with suspected malignant biliary 
obstruction and benign biliary disease (e.g. gallstone). 
2. Collect bile samples at first intervention in the biliary tree. 
3. Measure the concentration of different heavy metals (Copper, Zinc, 
Lead, Chromium, Nickel & Cadmium) in the bile samples collected 
from patients with biliary cancers and a control group with benign 
biliary. 
4. Compare the 2 groups using standard statistical methods and 
analyze any significant difference in any of the metal levels in the 2 
groups. 
5. Possible correlation of results with geological distribution of the 
diseases 
Although areas in the North-East of England have heavy industry, the degree 
of pollution is not as high when compared to previous similar studies from 
India or Egypt and we were concerned that there may not be measurable 
levels of heavy metals in the bile of local population in the North East of 
England. 
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In view of the nature of the study and the uncertainty of the logistics, it was 
decided to perform a feasibility study before embarking on a larger project. 
The aims of the pilot study were as follows: 
1. Collect bile sample from a small group of patients with suspected or 
proven hepato-biliary and pancreatic cancer and also from a control 
group of patients with gallstone disease. 
2. Examine the logistics of collecting the samples and find a method to 
make sure that all patients with suspected biliary cancer can be 
approached for the study. 
3. Carry out preliminary analysis of the bile samples in the laboratory in 
order to standardize the method of bile sample analysis.  
4. Carry out statistical analysis to compare groups in order to find the 
exact statistical tests to be used for the final study 
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3. Materials & Methods 
 
Subject and study design 
 
The present study was designed carefully with emphasis on including every 
single patient who was referred to the Freeman Hospital with suspected 
biliary cancer. Not all patients get referred with a definite diagnosis of biliary 
cancer. The majority of the patients with suspected cancer of the bile duct, 
gall bladder or pancreas have been investigated by at least an ultrasound 
scan or a computerized tomographic (CT) scan and there may be evidence 
of malignancy on these imaging modalities. One common presentation in 
most of these patients is the presence of jaundice.  This is caused by the 
partial or complete obstruction of the bile duct by the tumour. It is often the 
first complaint of the patient in this group of cancers. Because of the 
consistency of the symptom, we felt that all patients presenting to the unit 
with obstructive jaundice would be approached for the study. Based on 
previous publications, it was planned for two groups of patients to be studied 
- patients with biliary tract cancers and a control group of patients with non-
malignant hepatobiliary disorders such as gallstones.  
 
Consent forms and patient information sheet were designed after approval of 
the local Joint Ethics Committee (Appendix I & II, Joint Ethics Committee 
approval reference 2001/33). Every patient approached for the study had the 
opportunity to go through the information sheet and discuss with the 
investigator before consenting to take part in the study. It was our priority to 
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ensure that bile samples be collected from the patients with minimum 
discomfort or inconvenience to the patients.   
 
As part of their routine diagnostic procedure and treatment there were 
opportunities to obtain bile samples without additional risk to the patients. 
Patients with biliary tract cancers commonly undergo investigations and 
minimally invasive procedures or surgery, or both. Minimally invasive 
procedures are carried out both for investigation of malignant biliary 
obstruction as well as with a therapeutic intent to drain the biliary system by 
different types of stents to improve jaundice. Interventions include 
endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous 
transhepatic cholangiography (PTC). During these procedures the bile duct is 
accessed and bile samples can be aspirated. During surgery there is an 
opportunity for obtaining bile samples from both gall bladder and the bile 
duct. Since the gallbladder concentrates the bile it receives from the liver, the 
heavy metal concentration in the bile obtained from the gallbladder may be 
expected to be different from hepatic bile. Bile was, therefore, collected from 
both sources whenever possible to look for any significant difference. 
 
Patients with symptomatic gallstones or benign biliary obstruction were 
selected as controls. They may require surgery and some patients will 
require ERCP for diagnostic or therapeutic purposes. Bile samples can, 
therefore, be obtained from each group of patients without any additional 
procedure or added risk for the participants in the study. 
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Since obstruction to the bile duct causes jaundice, stagnation of bile or 
cholestasis may lead to changes in biliary heavy metal concentration, we 
proposed to carefully note the degree of biliary obstruction as shown by the 
liver function tests, including the bilirubin level at the time of collecting the 
bile to investigate the possible influence of biliary obstruction on the heavy 
metal concentration. A dataset of important patient variables and risk factors 
for the development of biliary tract cancers were established and recorded on 
a Microsoft Access Database created specifically for this project.  
 
A direct comparison was made between the levels of heavy metals in the 
hepatic and gallbladder bile in all subjects. Heavy metal concentration was 
correlated with conventional markers of cholestasis severity such as serum 
bilirubin level. Biliary concentration of heavy metals in cancer patients was 
compared with controls and the association (if any) between biliary heavy 
metal concentrations and the presence of malignancy (corrected for the 
presence of cholestasis) assessed. 
Bile Sample Analysis 
Collection, storage and handling of bile samples 
Patients were approached at the time of their attendance at the Freeman 
Hospital for their ERCP/PTC or before surgery. Hepatic bile was obtained in 
both groups during ERCP/PTC or during surgery. Gallbladder bile was 
obtained during operation in both groups. All samples were coded using a 
unique number and stored at the Research Unit freezer in the Freeman 
Hospital at - 84C till they were extracted for analysis. When a suitable 
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number of samples were collected for analysis, they were transported to the 
laboratory of the Department of Agriculture, Newcastle University, for 
analysis. All the samples were defrosted and thawed before the analysis 
began. 
As the samples were human products, a COSHH assessment was carried 
out and it was felt necessary that personnel handling these samples were 
vaccinated against Hepatitis B. Necessary precautions were taken to avoid 
biohazard and all unused samples and containers were destroyed by 
incineration. 
There were concerns about whether there will be measurable levels of heavy 
metals in the bile of patients from the North-East of England. Similar projects 
looking at heavy metal concentrations in bile were all from areas with high 
environmental pollution and high metal concentration in serum or bile was 
expected. We, therefore, decided to set up a pilot project to ascertain if 
adequate level of metal was present in the bile samples. This will also give 
us the opportunity to run the full process of analysing the samples and 
address any problems that can arise during laboratory work.  
Although the pilot project is part of the methods of this study, it is described 
in a separate chapter for ease of understanding and it also allows us 
integrate the data that emerges out of the pilot study with the main project. 
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4. Pilot Study 
 
As mentioned earlier, we were keen to ascertain whether there were 
measurable levels of heavy metals in the bile of patients in the North-East of 
England before embarking on a bigger project. The pilot study would also 
give us the opportunity to standardize the methods of bile sample analysis, 
which has never been done in our laboratories before. 
Standardisation of methodology – the initial samples 
Crude bile samples obtained from patients were not suitable for analysis in 
the spectrometer directly. The bile samples needed pre-treatment before the 
quantitative analysis for heavy metals in spectrometer and it is standard 
practice to pre-treat crude samples in this way. Two methods of pre 
treatment were assessed – syringe filtration method and acid digestion 
method. The samples were split in half, allowing for at least 5 ml to be set 
aside for the acid digestion method and the rest of the sample was syringe 
filtered.  
Syringe filtration method 
The tubes containing the samples were inverted 10 times to fully mix the 
contents. This prevents analysing only a fraction of the sample and ensuring 
that this method and the acid digestion method could be compared. Each 
sample was syringe filtered until there was approximately 2 ml of filtrate, an 
adequate amount to test for four metals – lead, cadmium, zinc and copper in 
the spectrometer.  
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Originally the samples were forced through a 0.5 μm filter attached to the end 
of the syringe. Unfortunately these filters were blocked with mucus very 
quickly and up to 6 or 7 filters were needed for each sample. This was 
relatively expensive and labour intensive method. It was therefore proposed 
to use a prefilter as well as the 0.5 μm filter for each sample and the method 
was successful. The filtrate was collected in plastic tubes with plastic lids and 
taken to the spectrometer for analysis. 
Acid digestion method  
The tubes containing the samples were, as with the syringe filtration method, 
inverted 10 times to fully mix the contents. 5 ml of sample was pipetted into 
glass digesting tubes with plastic leads and 5 ml of concentrated nitric acid 
was added to them and the samples left overnight. As soon as the acid was 
added there was a visible reaction with the sample changing colour to a clear 
pinkish solution usually and there was some coagulation of organic materials 
in the sample. The following day the samples were heated up to 120C over 
an 8-hour period in a Grant BT5 heating block to complete the digestion. 
After allowing them to cool overnight the samples were taken in plastic tubes 
for analysis in the spectrometer. 
Spectrometric analysis 
Both the syringe filtered and acid digested samples were subjected to 
spectrometric analysis. An ATI Unicom SolaaR 929 atomic absorption 
spectrometer was used with a deuterium background interference application 
for greater accuracy (Figure 4.1). Due to presence of large concentration of 
salts in the samples, the flame turned orange during analysis. It was prudent 
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to wait for the flame to lose the orange colour and therefore burn off all the 
salt before adding the next sample. The spectrometer was calibrated with 
standards before each session of sample analysis. Each sample was taken 
through the intake tube, which was placed in distilled water between each 
 
 
Figure 4.1: ATI Unicom SolaaR 929 atomic absorption spectrometer 
 
sample. The results for the syringe filtered samples were a direct 
measurement but with the acid digested samples the results needed to be 
doubled as the sample had been diluted by a factor of 2 by the acid. 
Results of pilot study – first 25 samples 
25 samples were analysed using both acid digestion and syringe filtration 
methods as part of the initial analysis. The results of these analyses were 
used to standardise the methods for subsequent samples. We have 
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compared the results of these 2 methods with the aim of choosing one of 
them as the standard method with the possibility that one of them will 
produce a higher or more measurable concentration of the metals in bile for 
subsequent analysis. 
Acid digestion versus syringe filtration 
Zinc 
There is no significant difference between acid digestion and syringe filtration 
methods on analysis. The mean concentration of zinc is smaller in acid 
digestion method than in syringe filtration method, and the difference is not 
statistically significant (P=0.33, Mann-Whitney U) (Figure 4.2) 
 
 
 
Figure 4.2: Comparison of acid digestion (AD) and syringe filtration (SF) method for 
concentration of zinc (Zn) 
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P = 0.33
(medians are indicated by lines) 
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Cadmium 
There was a large difference between the acid digested sample and the 
syringe-filtered samples. Acid digestion produced a much greater 
concentration of cadmium than syringe filtration. The difference between the 
median concentration of cadmium obtained by the two processes were 
statistically significant (P=<0.01) (Figure 4.3)  
 
 
Figure 4.3: Comparison of acid digestion (AD) and syringe filtration (SF) method for 
concentration of cadmium (Cd) 
 
Copper 
Both sets of samples had similar mean values with no major difference. They 
both had a close grouping of results around the median and a few very large 
values. Going back at those samples we noticed that the samples had been 
first collected in bottles with a brass cap and as brass is an alloy of copper 
and zinc, we thought it may produce erroneous results. However, not all 
samples stored in bottles with brass caps had high copper levels. In order to 
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(medians ar  i icated by lines) 
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avoid this possible source of error, all samples subsequently had been stored 
in glass containers with plastic caps. As evident from the figure, there was no 
statistical significance in the difference of means between the two groups 
(P=0.31) (Figure 4.4)  
 
 
Figure 4.4: Comparison of acid digestion (AD) and syringe filtration (SF) method for 
concentration of copper (Cu) 
 
Lead 
There was no measurable concentration of lead in the syringe-filtered 
samples and there was measurable concentration in the acid digested 
samples. Therefore to analyse the samples for lead concentration, we could 
only use the acid digestion method.  
The above finding for lead concentration and the significantly better results 
with cadmium meant that acid digestion would be the appropriate method for 
pre-treatment of bile samples before spectrometric analysis. After discussion 
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with agricultural scientists with vast experience of heavy metal assay for river 
water and soil samples where above methods of pre-treatment is commonly 
used, it was decided that acid digestion would be used as the standard 
procedure for pre treatment for the final analysis. 
Comparison between benign and malignant 
In the initial 25 samples, there were only 4 samples from the control group 
with benign biliary disease. The 2 groups were, therefore not balanced and 
direct comparison between the 2 groups was not appropriate. However, 
comparison was made for each metal between the 2 groups, none showing 
any significant result. A simple comparison of medians of the metal levels in 
the study group and the control group was done using non-parametric test 
(Mann-Whitney U). Lead and cadmium are the 2 metals that had the most 
difference in concentration between the 2 groups in the original study from 
India by Shukla et al. The results of these 2 metals are given below in the 
form of dotplots (Figure 4.5, Figure 4.6).  
Lead 
 
 
Figure 4.5: Comparison of median concentration of lead (Pb) in the bile samples from 
patients with benign and malignant diseases 
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Cadmium 
 
 
Figure 4.6: Comparison of median concentration of cadmium (Cd) in the bile samples 
from patients with benign and malignant diseases 
 
 A simple statistical analysis was also done to compare benign versus 
malignant samples from these initial 25 samples. Although this will be 
inadequately powered and the result of this analysis will be of no 
significance, it would help us to get an idea about the methods to be used for 
the final study. As evident from the above figures, there was no significant 
difference in the median level metals in the initial samples.  
The pilot study was very useful in clarifying the aims that we set out with. It 
confirmed that there was measurable level of heavy metals in the bile 
samples collected from patients in this part of the world. We could finalize an 
efficient method of collecting the samples and storing them. The bile sample 
analysis in the laboratory could be standardized and with the supporting 
evidence from above, we decided to use acid-digestion method of pre-
treatment as the standard method for the final project. We decided that data 
would be collected under the heading of individual metals and comparison 
(medians are indicated by lines) 
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done between malignant and benign group. As we are dealing with a rather 
rare disease group, we decided to combine the results of the assays done in 
the pilot study by the acid digestion method with the results of the main study 
so that we can get adequate number in each group for comparison. For 
comparing different groups, the median rather than the mean was taken as 
the measure of central tendency in the final analysis as the results are not 
normally distributed and non-parametric tests have been used to compare 
them. 
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5. Main Study 
 
Calculation of sample size 
A calculation of sample size was done on the basis of the original study from 
India (Shukla et al., 1998b). The difference in mean concentration of lead in 
study and control group was very high (58.38 mg/l vs 3.99 mg/l) and a 
calculation based on this with a significance of 0.05 and a power of 90% 
demonstrated that approximately only 13 patients are required in each group 
for a significant result.  Even calculation based on mean levels of cadmium, 
which had the least difference between the 2 groups (0.19 mg/l vs 0.09 mg/l), 
estimated approximately 27 patients in each group to demonstrate a 
significant result with same power.  However, it is unlikely that such large 
differences would be seen in the UK and therefore it was proposed that all 
patients with biliary malignancy would be included in the study over a period 
of one year. The majority of patients with biliary cancers in the North of 
England are referred to our institution and it was felt that it would be possible 
to recruit at least 50 patients with biliary cancers and a similar number of 
patients with gallstone disease to act as control over a period of 12 months. 
A significant difference in the concentration of heavy metals in the bile of 
these patients would be an important finding, particularly in the North of 
England, which is still an area of heavy industry. It would prompt further 
research into specific environmental pollutants and enable further 
collaboration with departments of occupational health, epidemiology and 
environment. 
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After completion of the pilot study, we continued collecting samples with the 
aim of collecting as many samples as possible to achieve at least 50 
samples in each group. This number was agreed after calculation of sample 
size as described earlier.  
Every patient attending Freeman Hospital with obstructive jaundice 
suspected to be due to a malignant biliary obstruction were approached for 
inclusion in the study. 
In the subsequent analysis, all the samples were treated by acid digestion as 
described above and underwent spectrometric analysis. Nickel and 
chromium were analysed in the original study from India and these 2 metals 
were also included in the study at this stage. The plan was to make a direct 
comparison of mean concentration of each individual heavy metal between 
the study group (malignant pancreato-biliary disease) and controls (benign 
pancreato-biliary disease). This formed the basis of subsequent analysis with 
all the bile samples. As described above, we tried to collect bile sample from 
every patient with suspected malignant biliary obstruction. The individual 
samples were formally allotted to the study group (malignant pancreato-
biliary disease) only after confirmation of diagnosis subsequently by positive 
histology, cytology or overwhelming radiological evidence of malignancy with 
raised tumour marker (CA19-9). If the radiological evidence or level of 
tumour marker were equivocal in a patient with biliary obstruction, we 
excluded such samples from the study.  
We recognized at this stage that the study group comprising of patients with 
malignant biliary obstruction might not be a homogenous group of patients. 
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Patients with pancreatic cancer and biliary cancer (bile duct 
cholangiocarcinoma or gallbladder cancer) will both present with malignant 
biliary obstruction but they suffer from completely different diseases and 
clinically, pathologically and as far as long term prognosis is concerned, they 
behave in very different ways. It was felt that once all the data were 
collected, it might be worthwhile looking at each individual subgroup causing 
malignant biliary obstruction to see if that influences the result. 
In order to facilitate data collection, we decided to create a database using 
Microsoft Access© software. It was a simple database where data entry could 
be done using the form view (Figure 5.1). Usual demographic data was 
collected. Attempt was made to collect data about smoking habits, possibility 
of heavy metal exposure and duration of exposure. Liver function test results 
were documented to see if presence of biliary obstruction had any effect on 
the concentration of biliary heavy metals. The source of the bile sample, i.e 
gallbladder or common bile duct, was also documented. The bile sample was 
collected during the first intervention in the bile duct, which could be 
endoscopic procedures like ERCP or radiological procedures like PTC. In 
either case the bile sample will be from the bile duct. On the other hand, the 
bile sample collected during surgery for benign disease like gallstone will be 
from gallbladder only. In patients undergoing resection for malignant disease, 
bile could be collected from both sources in order to have a set of samples 
where the bile was collected from two sources in the same patient and this 
subset would help us to see if there was any influence of the source of bile 
on the heavy metal concentration.  
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Figure 5.1: Data entry form for present study (Microsoft Access©) 
 
The data from this database could be directly transferred to any statistical 
software for analysis. We used SPSS Version 16© (SPSS Inc, USA) for all 
the statistical analysis and the results output from the software is directly 
incorporated into the result section of this document without any modification. 
The charts and diagrams were produced by the same software using the 
same data, thereby minimizing the chance of error from using multiple 
softwares. 
Results of main study 
 
The results for the study were analyzed with the aim of comparing the mean 
concentration of each individual metal amongst the different study groups i.e. 
biliary cancer and benign biliary disease. As discussed in the methods of this 
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study, the samples of bile were collected from every patient with presumed 
malignant biliary obstruction, as it was not possible to have a definite 
histological or cytological diagnosis in all cases before their first intervention 
to the biliary tree. This was the only way of making sure that all the patients 
with possible biliary cancer could be potentially included in the study group. 
Once the final diagnosis was established, by cytology or histology or imaging 
with supporting elevated tumour marker, the individual samples were then 
allotted to the different study groups. 
 
We followed a definite plan for the analysis of the final results. 
1. Analyze the demographics of the patients from whom the samples 
were obtained 
2. To ascertain whether the source of bile, either from common bile duct 
or gallbladder, has any impact on the metal concentration. 
3. To ascertain whether the presence of biliary obstruction has any 
impact on metal concentration 
4. Calculate the mean concentration of each individual metals and 
compare their levels between the malignant groups and the benign 
control group 
 
One hundred and sixty two patients were approached for taking part in the 
study over a period of 20 months. This included all the patients with 
presumed malignant biliary obstruction and the patients with benign biliary 
disease (e.g. gallstones) as the control group. One hundred and twenty nine 
patients agreed to take part in the study and ultimately 107 patients were 
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recruited after excluding the patients who already had metal stent placed in 
the biliary tree before referral, or already started palliative chemotherapy or 
radiotherapy before inclusion. 
 
.A total of 140 samples were collected from the 107 patients recruited for the 
study and in 33 patients, bile was collected from 2 sources (CBD and GB). 
The table below summarises the sources and number of bile samples used 
for final analysis (Table 5.1). 
 
After excluding cases for inadequate samples and pathological diagnosis not 
directly related to biliary epithelial tumours (e.g. neuroendocrine tumours), we 
had a total of 127 samples to analyze.  Specific statistical tests used for 
comparing groups are mentioned for specific analysis and results. 
 
 Total number of patients approached for the study   162 
 Total number of patients recruited     107 
 Total number of samples of bile     140 
 33 patients had samples from 2 sources (CBD or GB) 
 74 patients had sample from a single source, either CBD or GB 
 3 excluded due to histological diagnosis – carcinoid/neuroendocrine tumour 
 1 sample from above 3 had inadequate volume for analysis 
 10 more samples excluded for inadequate volume 
 Total number of samples analyzed {140 – (10+3)} = 127 
 
Table 5.1: Details of analyzed samples 
 
 86 
Age and Sex distribution  
The total number of 127 samples came from 98 patients. The median age of 
the study population was 65.00 years (Standard deviation 12.87years, range 
20 - 82 years). The age distribution is shown in the table (Table 5.2) and 
histogram below (Figure 5.2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Histogram of the age distribution of the study population 
 
The whole cohort of patients comprised of 55 female and 43 male patients. 
The sex distribution is depicted in the figure below (Figure 5.3). 
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Total Number of Patients 98 
Mean Age in years 62.18 
Std. Error of Mean 1.300 
Median 65.00 
Std. Deviation 12.867 
Minimum in years 20 
Maximum in years 82 
Table 5.2: Age distribution of the study population 
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Figure 5.3: Sex distribution of all the patients 
 
According to the aims of the study, analysis was carried out to compare the 
individual metal levels between the groups of patients with biliary malignancy 
versus those with benign biliary disease. As explained earlier, all patients 
with assumed malignant biliary obstruction were initially placed in the study 
group. However, we accepted that this study group will not be a homogenous 
group, as there will be different causes of malignant biliary obstruction. It was 
decided that to include a patient in this study, there must be either a 
histological or cytological diagnosis either by brush cytology from the bile 
duct, histology from endoscopic specimen or histology of resected 
specimens, or there must be overwhelming evidence of malignant process 
on imaging or endoscopic investigation along with a raised tumour marker 
(CA19-9) to support the diagnosis of malignancy. With this inclusion criteria, 
68 patients (69.4%) had a positive histology or cytology to confirm 
malignancy and 30 patients (30.6%) were diagnosed on the basis of imaging 
and tumour markers. When the final diagnosis was available, it became 
apparent that the samples belong to essentially 4 groups of patients (Figure 
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5.4). Pancreatic cancer is a distinctly different disease both clinically and 
prognostically from either biliary or periampullary cancer and therefore we felt 
that for the purpose of discussion and analysis of results, these different 
types of cancers should be considered separately and not as a broad group 
of malignant diseases. 
 
 
Figure 5.4: Histological diagnosis (CA = Carcinoma) 
 
Age and sex distribution according to diagnosis 
Once it was established that the analysis would be based on these four study 
groups, statistical analysis was done to assess the age and sex distribution 
of each group to see if there was any difference between the groups.  
Diagnosis N Median 
Std. 
Deviation 
95% Confidence Interval for 
Mean 
Minimum Maximum 
Lower Bound Upper Bound 
Pancreatic 
Carcinoma 
43 66.00 9.587 61.61 67.51 33 82 
Biliary 
Carcinoma 
25 71.00 7.826 65.85 72.31 51 81 
Benign 43 57.00 14.137 51.30 60.00 20 78 
Periampullary 
Carcinoma 
16 69.50 7.856 63.44 71.81 54 77 
Total 127 65.00 12.064 60.70 64.94 20 82 
 
Table 5.3: Age distribution of individual groups of patients 
 
BenignPeriampullary CABiliary CAPancreatic CA
Diagnosis
50
40
30
20
10
0
F
re
q
u
e
n
c
y
16
12.6%
43
33.86%
25
19.69%
43
33.86%
 89 
 
Figure 5.5: Age distribution of individual groups of patients 
 
Descriptive statistics of individual groups and their mean age (Table 5.3) is 
shown above along with a box plot showing the mean (Figure 5.5). As would 
be clinically expected, the mean age of the benign group (55.65 yrs, standard 
deviation 14.14, range 20 – 78 years) appeared to be lower than all the 3 
other groups with malignant disease. To test whether the difference in the 
mean was significant or not, they were compared using one-way ANOVA and 
the result suggests that there is significant difference between the groups 
(p<0.0001). It is to be noted, this test does not compare one particular group 
from another, but compares differences between all the 4 groups. The 
significant difference in means suggests the groups are not age-matched and 
this is likely to be contributed mostly by the lower mean age of the benign 
group. 
Sex distribution according to diagnosis was analyzed using a similar strategy. 
The sex versus diagnosis cross tabulation is shown below (Figure 5.6). 
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Figure 5.6: Sex distribution according to diagnosis 
 
To test if there is any difference in the sex distribution amongst the different 
groups, a Chi-square test was done on the cross table and the result is given 
below (Table 5.4). 
 
 Value Df 
Significance 
(2-sided) 
Pearson Chi-Square 1.521 3 0.678 
Likelihood Ratio 1.525 3 0.676 
N of Valid Cases 127   
 
Table 5.4: Sex distribution vs. diagnosis (Chi-Square Test) 
 
As the table suggests, there is no significant difference between groups in 
their sex distribution (p=0.68). The groups are reasonably sex matched.  
Regional variation  
The main source of heavy metals in the body is from environmental 
exposure. All the samples were from patients in the North-East of England, 
which has significant variation in level of industrialization. Although the level 
BenignPeriampullary CABiliary CAPancreatic CA
Diagnosis
25
20
15
10
5
0
C
o
u
n
t
Male
Female
Sex
 91 
of exposure will depend on a number of factors including duration of 
residence near possible sources, occupation etc, a base line analysis was 
done to see if there was a difference in the groups regarding which part of 
the North East of England they came from. The region was divided into North 
and South on the basis of the postcodes as the southern part has more 
heavy industry than the north. The results are given in Table 5.5 and Figure 
5.7  below. 
Regional distribution of 
patients 
Diagnosis 
Total 
Pancreatic CA Biliary CA Benign Periampullary CA 
Post Code North 23 19 31 9 82 
 South 20 6 12 7 45 
Total 43 25 43 16 127 
 
Table 5.5: Distribution of patients from the North and South of the region depending 
on the post code 
 
 
Figure 5.7: Distribution of patients into North and South of the region according to 
diagnosis 
  
From the bar chart there appears to be a difference in the number of benign 
specimens with samples from the north being more than the south. This is 
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expected as the benign diseases from the south of the region are more likely 
to be treated locally and not referred to a tertiary centre. However, a Chi 
square test on the cross table did not show any significant difference in 
distribution of the samples originating from the north or south of the region 
(p=0.15)  
Variation in levels of obstruction to the biliary tree in different groups 
Some of the patients, especially those in the groups with malignant disease, 
presented with jaundice secondary to bile duct obstruction. There may be a 
potential influence of presence of significant number of obstructed patient in 
any particular group. A serum bilirubin level of over 35 μmol/L was taken as a 
cut off and all patients with serum bilirubin higher than that was considered to 
be having an obstructed biliary system. 
 
 
Figure 5.8: Distribution of patient depending on presence of biliary obstruction (serum 
bilirubin level >35 μmol/L) 
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As appears from the bar chart above (Figure 5.8), there seems to be a 
notable difference among the groups in the degree of biliary obstruction. A 
Chi square test was done on the cross table and it confirms that there are 
significant difference between the groups (p<0.0001). 
Source of bile – common bile duct (CBD) or gallbladder (GB) – effect on 
biliary metal concentration 
As explained earlier, bile sample for this study was collected from CBD or GB 
or from both sources whenever possible. It was reasonable to expect some 
change in concentration of the metals in the bile from gallbladder as 
gallbladder concentrates bile. However, no concrete evidence was available 
in the literature that there is significant difference in concentration of heavy 
metals excreted in bile sampled from the CBD and the GB. Unfortunately, 
due to rarity of the diseases investigated in the study, we had get the 
samples from whatever sources available and we could only get samples 
from both sources in patients undergoing resection for biliary obstruction. 
Thirty-three such patients were identified where we had sample from both the 
sources (66 samples). It was decided to use these samples to try and find a 
relation between the concentration in GB sample and the CBD sample of 
each metal. We decide to exclude the samples, which had evidence of biliary 
obstruction in order to avoid the possible influence of obstructed biliary 
system. 5 sets of samples were excluded due to inadequate volume or biliary 
obstruction and analysis was done using 28 set of samples. 4 metals were 
analyzed – zinc, copper cadmium and lead. Standard Pearson correlation 
analysis was done. 
 94 
 
Zinc 
 
Descriptive Statistics 
 Mean Std. Deviation N 
ZincCBD .96068 .894167 28 
ZincGB 1.39196 1.796878 28 
 
Correlations 
 ZincCBD ZincGB 
ZincCBD Pearson Correlation 1 .532 
 N 28 28 
ZincGB Pearson Correlation .532 1 
 N 28 28 
 
 
 
Table 5.6: Zinc level from samples taken from gallbladder (GB) and common bile duct 
(CBD) – correlation statistics 
  
 
 
 
Figure 5.9: Graphical representation of correlation between zinc level of samples from 
gallbladder (GB) and common bile duct (CBD) 
 
 
Pearson correlation coefficient was 0.532 for zinc obtained from CBD versus 
the samples from CBD (Table 5.6). The closer the value is towards 1.00, 
stronger is the correlation. The above value signifies moderate correlation 
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between the levels of zinc obtained from CBD and GB (Figure 5.9). Similar 
analysis was done for all the other 3 metals.  
Copper 
 
Descriptive Statistics 
 Mean Std. Deviation N 
CopperCBD .6559 .55542 27 
CopperGB .7647 .69333 27 
 
Correlations 
 CopperCBD CopperGB 
CopperCBD Pearson Correlation 1 .862 
 N 27 27 
CopperGB Pearson Correlation .862 1 
 N 27 27 
 
 
 
Table 5.7: Copper level from samples taken from gallbladder (GB) and common bile 
duct (CBD) – correlation statistics 
 
 
 
 
Figure 5.10: Graphical representation of correlation between copper level of samples 
from gallbladder (GB) and common bile duct (CBD): 
 
 
The Pearson correlation coefficient for copper is 0.862 suggesting a strong 
correlation between the 2 values (Table 5.7, Figure 5.10). 
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Cadmium 
 
Descriptive Statistics 
 Mean Std. Deviation N 
CadmiumCBD .8151 .95143 24 
CadmiumGB .9680 1.18159 21 
 
Correlations 
 CadmiumCBD CadmiumGB 
CadmiumCBD Pearson Correlation 1 .947 
 N 24 21 
CadmiumGB Pearson Correlation .947 1 
 N 21 21 
 
 
Table 5.8: Cadmium level from samples taken from gallbladder (GB) and common bile 
duct (CBD) – correlation statistics 
 
 
 
Figure 5.11: Graphical representation of correlation between cadmium level of 
samples from gallbladder (GB) and common bile duct (CBD) 
 
The Pearson correlation coefficient for cadmium is 0.947 signifying a strong 
correlation between CBD and GB samples (Table 5.8, Figure 5.11). 
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Lead 
 
Descriptive Statistics 
 Mean Std. Deviation N 
LeadCBD .2266 .17862 14 
LeadGB .2571 .22615 15 
 
Correlations 
 LeadCBD LeadGB 
LeadCBD Pearson Correlation 1 .675 
 N 14 12 
LeadGB Pearson Correlation .675 1 
 N 12 15 
 
 
 
Table 5.9: Lead level from samples taken from gallbladder (GB) and common bile duct 
(CBD) – correlation statistics 
 
 
 
 
Figure 5.12:  Graphical representation of correlation between lead level of samples 
from gallbladder (GB) and common bile duct (CBD) 
 
 
The Pearson correlation coefficient for lead is 0.675, which suggest a fairly 
strong correlation (Table 5.9, Figure 5.12).  
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The above correlation study suggests that there is a correlation between the 
concentrations of the metals sampled from GB or CBD. However this 
correlation is variable and copper and cadmium samples seem to have the 
strongest correlation between the 2 sources. It is, however, not possible to 
comment if there is any statistically significant difference between the 
correlation of each metal. 
 
We can assume from the above study that all the four metals under 
consideration, i.e. zinc, copper, cadmium and lead are excreted in bile in 
variable quantities. Although the bile is concentrated in the gallbladder 
compared to the bile in the common bile duct, no studies were found in 
literature in either human or animal model that has demonstrated that heavy 
metals are present at a higher concentration in bile obtained from gallbladder 
compared to the bile from common bile duct. The above analysis of 
correlation between the concentration of each metal sampled from GB or 
CBD suggests that there is probably no significant difference between the 
two sources. It is, therefore, proposed that for the final analysis of difference 
in heavy metal concentration between different study groups, we will perform 
the comparison taking one representative sample (from GB or CBD) from 
each patient in the group of 33 patients where we had sample from both 
sources (CBD or GB). The sample of bile taken from CBD is likely to be the 
more accurate representation of biliary excretion of heavy metal as this is the 
sample of bile directly secreted from liver without being stored or 
concentrated in the gallbladder. Comparison between different study groups 
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was, therefore, done using the sample from CBD in those subjects where we 
had sample from both sources. Each subject had one unique sample for 
comparison and final analysis. 
Obstructed biliary system – effect on biliary metal concentration 
Continuing the above discussion on possible effect of source of bile on the 
metal concentration, we also felt that the presence or absence of biliary 
obstruction may effect the heavy metal concentration. Patients with biliary 
obstruction are those patients with obstruction in flow of bile in the common 
bile duct (CBD). This is clinically manifested by jaundice and the obstruction 
can be caused buy the tumour itself in patients with malignant disease or by 
benign strictures or stones in patients with benign disease. The incidence of 
biliary obstruction is higher in the malignancy than in benign disease in 
general and the same is seen in our series (Figure 5.13). Therefore, when  
 
Figure 5.13: Distribution of patient depending on presence of biliary obstruction 
(serum bilirubin level >35 μmol/L) 
 
 
we compare the heavy metal levels between the benign and malignant 
groups, the malignant group will have more patients with biliary obstruction 
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and it seems logical to explore the possible influence of biliary obstruction on 
the concentration of each heavy metal in our study. 
 
The strategy for this analysis was similar to the one used for looking at 
influence of source of bile (CBD or GB) in the previous section, i.e., Pearson 
correlation analysis. The degree of biliary obstruction is represented by the 
bilirubin level and that was correlated with the concentration of each heavy 
metal in the study. A bilirubin level higher than 35 mol/lit was selected as a 
sample with biliary obstruction in order better demonstrate the difference 
between obstructed and non-obstructed samples. This level of bilirubin is 
usually chosen in most studies to indicate biliary obstruction and is also used 
to select patients for clinical trials involving chemotherapeutic drugs. Each 
metal has been analyzed separately as in the previous section. 
Zinc 
 
The mean Level of zinc in all the samples was correlated with the bilirubin 
level of blood at the time of collection of the sample. As discussed the 
previous section, Pearson correlation coefficient is 1.00 when there is 
complete positive correlation between the 2 values being assessed (Table 
5.10). 
 
 Bilirubin Level Zinc 
Bilirubin Level 
Pearson Correlation 1.000 -.094 
N 127 127 
Zinc 
Pearson Correlation -.094 1.000 
N 127 127 
 
Table 5.10: Correlation between bilirubin level and zinc concentration 
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Similarly, a value of -1.00 signifies a complete negative correlation. Pearson 
correlation coefficient for zinc in our experiment -0.094, signifying a rather 
weak negative correlation. The same fact is demonstrated in Figure 5.14, 
showing no linear relation between the mean level of zinc and bilirubin level. 
 
 
Figure 5.14: Graphical representation of correlation between bilirubin level and zinc 
concentration 
 
Copper 
 
Pearson correlation coefficient for copper in our study was -0.185, 
suggesting a weak negative correlation between copper levels and billirubin 
levels (Table 5.11).  This is again shown in the diagram below (Figure 5.15). 
 
  Bilirubin Level Copper 
Bilirubin Level 
Pearson Correlation 1.000 -.185 
N 127 122 
Copper 
Pearson Correlation -.185 1.000 
N 122 127 
 
Table 5.11: Correlation between bilirubin level and copper concentration 
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Figure 5.15: Graphical representation of correlation between bilirubin level and copper 
concentration 
 
 
 
Cadmium 
 
Like zinc and copper, cadmium also has a very weak, but this time positive 
correlation with the bilirubin level of the patient (Pearson correlation 
coefficient of 0.079) (Table 5.12). The scatter plot also shows widely 
distributed values with no linear relationship (Figure 5.16).  
 
  Bilirubin Cadmium 
Bilirubin 
Pearson Correlation 1.000 .079 
N 127 110 
Cadmium 
Pearson Correlation .079 1.000 
N 110 110 
 
Table 5.12: Correlation between bilirubin level and cadmium concentration 
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Figure 5.16: Graphical representation of correlation between bilirubin level and 
cadmium concentration 
 
 
Lead 
 
Pearson correlation coefficient for lead is 0.282. This follows the same trend 
as other metals with having a weak correlation with bilirubin level (Table 
5.13). It is interesting to note that this value is closest to 1.0 amongst all the 
four metals and therefore lead has the strongest correlation with the bilirubin 
level in our study. This finding is demonstrated in the scatter plot where the 
values are more closely distributed around the line of best fit (Figure 5.17). 
Even then  
  Bilirubin Level Lead 
Bilirubin Level 
Pearson Correlation 1.000 .282 
N 127.000 74 
Lead 
Pearson Correlation .282 1.000 
N 74 74.000 
 
Table 5.13: Correlation between bilirubin level and lead concentration 
 
the distribution is not linear and the correlation is weak. Any values above 0.5 
are taken as strong correlation between 2 values in statistical terms. 
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Figure 5.17: Graphical representation of correlation between bilirubin level and lead 
concentration 
 
 
This lack of correlation between the mean level of heavy metals and the 
bilirubin in our study meant that the levels of heavy metals in the bile did not 
depend or get influenced by biliary obstruction, at least in our study 
population. It will not be reasonable to conclude from this analysis that such 
influence does not exist, but this analysis will allow us to ignore possible 
influence of biliary obstruction in our study when we compare the heavy 
metals levels between different study groups with benign and malignant 
diseases. 
Comparison between groups for each metal – the final analysis 
This analysis was done taking a single sample (CBD) from the group of 33 
that had 2 samples (i.e using single primary sample from each patient). This 
was done to exclude 2 samples from the same patient, which would 
obviously skew the result. The CBD sample was considered the most 
representative sample as it is directly being excreted from the liver and not 
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being concentrated in the gallbladder. However, we have demonstrated the 
previous section that there is strong correlation between the metal levels 
from either sources in our study and therefore a representative sample can 
be taken from either sources for the final analysis.  
 
Table 5.14: Raw data of each metal concentration among different groups of patients 
 
The date used for analysis is shown in Table 5.14. A one-way ANOVA was 
performed to look for difference between groups. The advantage of using this 
test is that it is very useful in looking at differences in mean between more 
than 2 groups and can be used as a preliminary test to assess if there is any 
significant difference between the groups. At the end of the final study we 
had 4 distinct groups to look at and compare i.e. pancreatic cancer, biliary 
cancer, periampullary cancer and the benign control group. It was felt that 
ANOVA would be the most appropriate initial test to look at difference 
between the groups (Table 5.15). 
28 1.10357 .759031 .143443 .80925 1.39789 .059 3.192
22 1.17386 1.002924 .213824 .72919 1.61854 .040 3.769
38 1.65937 1.971297 .319787 1.01142 2.30732 .023 9.600
10 .80880 .777259 .245791 .25278 1.36482 .040 2.660
98 1.30479 1.416568 .143095 1.02078 1.58879 .023 9.600
26 .62265 .921704 .180761 .25037 .99494 .048 4.871
22 .69223 .703798 .150050 .38018 1.00427 .000 2.650
36 1.73267 1.880851 .313475 1.09628 2.36906 .039 7.044
10 .79580 .618722 .195657 .35319 1.23841 .034 1.730
94 1.08247 1.405788 .144996 .79453 1.37040 .000 7.044
25 .84864 1.063557 .212711 .40963 1.28765 .020 3.266
20 1.41875 1.448307 .323851 .74092 2.09658 .026 4.722
34 .41497 1.002480 .171924 .06519 .76475 .020 4.743
9 .78511 1.024381 .341460 -.00230 1.57252 .040 2.950
88 .80416 1.180871 .125881 .55396 1.05436 .020 4.743
17 .29753 .194254 .047114 .19765 .39741 .041 .608
18 .45828 .301283 .071013 .30845 .60810 .065 1.370
20 .21865 .255779 .057194 .09894 .33836 .000 .892
4 .12550 .106221 .053111 -.04352 .29452 .040 .280
59 .30817 .266685 .034719 .23867 .37767 .000 1.370
Pancreatic CA
Biliary CA
Benign
Periampullary CA
Total
Pancreatic CA
Biliary CA
Benign
Periampullary CA
Total
Pancreatic CA
Biliary CA
Benign
Periampullary CA
Total
Pancreatic CA
Biliary CA
Benign
Periampullary CA
Total
Zinc
Copper
Cadmium
Lead
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
Minimum Maximum
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Table 5.15: Results of ANOVA to look at the differences between groups of patients 
 
 
The results of ANOVA suggested significant differences between groups for 
copper (p=0.004), cadmium (p=0.025) and lead (p=0.016). Form the ANOVA 
test itself it is impossible to comment whether any particular group is 
contributing to the significant difference among the groups. However, it helps 
us with the information that there is significant difference in the mean level of 
the 3 above metals between the groups and therefore it is justified to pursue 
this further by looking at each individual metal under study. 
 
Another strategy was to look at the mean level of each metal in each group of 
the patient and that will give us and idea about possible influences by each 
group to the above significant difference on the ANOVA. The means plot for 
each metal shown below suggests that these significant differences are 
probably contributed by high level of copper in the benign group and high 
levels of cadmium and lead in the biliary cancer group ( 
Figure 5.18). 
 
 
8.748 3 2.916 1.475 .226
185.898 94 1.978
194.647 97
24.889 3 8.296 4.699 .004
158.902 90 1.766
183.790 93
12.757 3 4.252 3.290 .025
108.561 84 1.292
121.318 87
.701 3 .234 3.755 .016
3.424 55 .062
4.125 58
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Zinc
Copper
Cadmium
Lead
Sum of
Squares df Mean Square F Sig.
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Mean Plot for each metal 
 
 
Figure 5.18: Means plot of zinc, copper, cadmium and lead concentration in each 
group of patients 
 
 
On the basis of the above analysis, we planned to compare the mean or 
median concentration of each metal between the individual cancer groups 
versus the benign group to look for significant differences using non-
parametric test (Mann-Whitney U test). As discussed in the pilot study, the 
median has been the preferred value in the analysis as the results are not 
normally distributed. The results for each metal are shown below. 
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Box plot of zinc level shown in the figure suggests very similar concentrations 
in each group. There was no significant difference in the level of zinc 
between the groups when each of the cancer groups (pancreatic cancer, 
biliary cancer and periampullary cancer) was compared with the benign 
group by non-parametric test (Figure 5.19).  
 
 
 
 
Figure 5.19: Box plot comparing median concentration of zinc between different 
groups of patients 
 
Copper 
Copper levels were compared in a similar fashion. The median level of 
copper was higher in the benign group. The median levels of copper were 
compared between the groups as with zinc. There was statistically significant 
difference in the levels of copper when comparing pancreatic cancer versus 
benign group (p=0.006) and biliary cancer versus benign (p=0.016). There 
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was no significant difference when periampullary cancer was compared 
against the benign group (Figure 5.20).  
Cadmium 
 
From the bar chart it appears that the median level of cadmium is higher in 
the biliary cancer group. The difference is statistically significant when 
compared to benign group (p=0.007). There is significant difference in 
cadmium levels when pancreatic cancer was compared with the benign 
 
 
Figure 5.20: Box plot comparing median concentration of copper between different 
groups of patients 
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Figure 5.21: Box plot comparing median concentration of cadmium between different 
groups of patients 
 
 
group (p=0.03). There was no difference when the periampullary cancer 
group was compared with the benign group (Figure 5.21). 
Lead 
 
From the figure below (Figure 5.22), the mean level of lead in biliary cancer 
group appears higher and when compared with the benign group there is a 
significant difference (p=0.005). There was no difference when pancreatic 
cancer and periampullary cancer were compared to the benign group. 
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Figure 5.22: Box plot comparing median concentration of lead between different 
groups of patients 
 
In summary, both cadmium and lead were present at a significantly higher 
concentration in the biliary cancer group compared to the benign control 
group. Cadmium was also present at a significantly higher level in pancreatic 
cancer group compared to the control. There are numerous reports of 
cadmium and its association with pancreatic cancer. The possible 
association of both cadmium and lead will be explored and discussed in the 
next section. There are also reports of copper and its association with biliary 
cancer, although that is not supported by this study.  
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6. Discussion 
 
Secretory and excretory functions of bile 
 
Bile is a detergent rich fluid secreted by the liver into the intestinal tract in 
almost all vertebrates. The gallbladder, a reservoir for bile in the form of a 
pouch from the biliary tree in between the liver and the intestine, is present in 
most vertebrates and some birds. Bile is not only stored in the gallbladder, 
but it is also concentrated and intermittently discharged into the biliary 
system during digestion. Along with saliva, gastric and pancreatic juice, bile 
helps in assimilation of food. As far as digestion of food is concerned, the 
most important constituent of bile is the bile salts. Bile salts are water-soluble 
end products of cholesterol metabolism formed by conjugating a bile acid to 
taurine and glycine. The anions of such conjugated bile salts are 
impermeable to cell membrane and have the ability to dissolve biliary 
phophatidylcholine, as well as breakdown products generated by pancreatic 
lipases. The final product of such lipolysis is mostly fatty acid. Long chain 
fatty acids are poorly soluble in the pH of the small intestine because of 
formation of acid soaps that have very low solubility at the slightly acidic 
media of jejunum. However, the partly ionized fatty acids readily form mixed 
micelles with bile salts. Solubilisation with micelle formation increases the 
amount of fatty acid present in the aqueous phase by a thousand fold. 
Because of their size, micelles diffuse more slowly than single molecule, but 
the increased amount of fatty acid present in this form increases the overall 
diffusion of long chain fatty acids. Fatty acids that are water-soluble do not 
require this mechanism for absorption. 
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As an excretory fluid, bile contains substances that cannot be eliminated 
efficiently in urine because they are either insoluble or protein bound. These 
include bile acids (as end products of cholesterol metabolism), bilirubin (end 
product of haem metabolism), and heavy metals such as iron, copper etc. 
The metals are usually derived from synthesis or absorption in excess of the 
needs of the body.  
Physiology of bile secretion 
Bile secretion starts in the canaliculus of hepatocytes (‘canalicular bile’; about 
75% of daily bile production) and is modified along the bile ductules and 
ducts (‘ductular bile’; 25% of biliary secretion). Canalicular bile is formed by 
osmotic filtration of water and electrolytes in response to osmotic gradients  
 
 
 
Figure 6.1: Mechanisms of bile formation. Bile formation begins at the canalicular 
level (‘canalicular bile’; 75% of daily bile production), followed by modifications along 
the bile ducts (‘ductal bile’; 25%)(Ferenci et al., 2002) 
 
 
created by the active transport systems for bile salts and other organic 
anions, located at basolateral and canalicular membranes. The main 
determinant of canalicular bile formation is excretion of bile salts into the 
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canaliculus (‘bile salt dependent’ bile flow). Canalicular excretion of reduced 
glutathione (GSH) and bicarbonate (HCO3
-) constitute the main component of 
the ‘bile salt independent’ fraction of the bile flow. Normal secretion of bile 
depends on  
1. Active transport system across the membrane generating the osmotic 
gradient for bile flow.(Muller and Jansen, 1997, Muller and Jansen, 
1998) 
2. Intact cell morphology for movement of vesicles and bile canalicular 
contraction. 
3. Cell contact and maintenance of cell polarity  
4. Signal transduction mechanisms regulating various processes 
involved in bile formation (Figure 6.1) (Ferenci et al., 2002). 
The active transport systems across cell membranes are of main interest in 
understanding heavy metal ion transport in the liver and their excretion in 
bile. The hepatocyte is polarized with basolateral (sinusoidal) and apical 
(canalicular) plasma membrane domains. Uptake of biliary constituents in the 
liver occurs at the basolateral membrane, which is in contact with sinusoidal 
blood via the space of Disse. A Na+ - dependent Na+/taurocholate co-
transporter (NTCP) is the main transporter for bile salts (Hagenbuch and 
Meier, 1994, Hagenbuch et al., 1991). There is also an increasing number of 
Na+-independent organic anion transporting protein (OATP) transporters not 
only for bile acids, but also for other organic anions like bilirubin and other 
cationic drugs. Na+-dependent bile salt transport by NTCP is driven by a Na+- 
K+-ATPase which generates an inwardly directed Na+ gradient (Kullak-Ublick, 
1999). 
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The canalicular membrane contains both adenosine triphosphate (ATP)-
dependent and ATP-independent transport systems. ATP-dependent 
transport systems (ATP binding cassette (ABC) proteins) transport 
constituents of bile against a concentration gradient. Most of these ABC 
proteins belong to the multi-drug resistance protein (MDR) or multi-drug 
resistance–associated protein (MRP) gene superfamily. There are several 
varieties of MDR/MRP with specific transport functions. 
 
A conjugate export pump (MRP), functionally also known as the canalicular 
multispecific organic anion transporter (cMOAT), mediates canalicular 
excretion of a wide variety of organic anions, most of which are conjugated 
with glutathione, glucuronate and sulfate formed by conjugation in 
hepatocytes (Buchler et al., 1996). Other forms of MRP, such as MRP1 and 
MRP3 are also present in basolateral membrane and act as compensatory 
overflow system, especially under cholestatic condition with impaired 
canalicular MRP2 function (Konig et al., 1999, Kool et al., 1999). Mutations of 
genes coding for these transport proteins result in several hereditary 
cholestatic conditions. Although they are rare conditions, they provide 
interesting insight into biliary pathophysiology and help to understand the 
mechanism of various canalicular transport systems. Moreover, genetic 
transporter mutation and polymorphism may remain initially subclinical but 
may increase susceptibility to cholestatic challenges in adult life, for example 
during pregnancy or drug-induced cholestasis. 
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Understanding the mechanism of copper transport in the liver has been a 
major contribution to the knowledge of metal transport across biliary 
epithelium. Dietary copper intake far exceeds the normal daily requirement. 
Most of the ingested copper is taken up by the liver by a carrier mediated, 
energy independent mechanism (Figure 6.2) (Ferenci et al., 2002). In the 
hepatocytes, glutathione (GSH) has an affinity for copper and Cu+-GSH 
complexes are formed. Cu+-GSH works as an intracellular Cu+ transport and 
also acts as a donor to metallothionein and superoxide dismutase.  
 
Figure 6.2: Copper transport in human liver. Copper taken up from blood (via CTR) is 
taken up by metallothionein, which is the storage protein for a variety of metal ions 
including zinc and copper (Ferenci et al., 2002) 
 
Metallothionein is a low molecular weight, cytosolic, cystein-rich, metal 
binding protein. Copper stored in metallothionein can be donated to other 
proteins either by degradation in lysosomes, or by exchange through GSH-
complex formation. Metallothionein plays a role in the homeostasis of 
essential metals such as zinc and copper, detoxification of toxic metals such 
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as cadmium and protection against oxidative stress.  Metallothionein plays a 
minimal role in the gastrointestinal absorption of cadmium, but it plays 
important roles in cadmium retention in tissues and significantly decreases 
biliary excretion of cadmium. Cadmium bound to metallothionein is 
responsible for cadmium accumulation in tissues and the long biological half-
life of cadmium in the body. Induction of metallothionein protects against 
acute cadmium induced death, as well as acute toxicity to the liver and lung. 
Intracellular metallothionein also plays important roles in ameliorating 
cadmium toxicity following prolonged exposures, particularly chronic 
cadmium induced nephrotoxicity, osteotoxicity, and toxicity to the lung, liver, 
and immune system. There is an association between human and rodent 
cadmium exposure and prostate cancer. Metallothionein expression in 
cadmium-induced tumors varies depending on the type and the stage of 
tumor development. For example, high levels of metallothionein are detected 
in cadmium-induced sarcomas at the injection site, whereas the sarcoma 
metastases are devoid of metallothionein (Klaassen et al., 1999). The use of 
metallothionein-transgenic and metallothionein-null mice has greatly helped 
define the role of metallothionein in cadmium toxicology, with the 
metallothionein-null mice being hypersensitive and metallothionein-
transgenic mice resistant to cadmium toxicity (Liu et al., 2001). Thus, 
metallothionein is critical for protecting human health from cadmium toxicity. 
There are large individual variations in metallothionein expression, which 
might in turn predispose some people to cadmium toxicity (Klaassen et al., 
2009). It is difficult to comment on the association of metallothionein 
expression and its relation to cadmium induced tumours or tumours that have 
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association with cadmium exposure.  A study from India from an area of 
heavy metal pollution, reported that metallothionein expression was 
significantly higher in cases with carcinoma of the gallbladder (70.37%) as 
compared to chronic cholecystitis (25%) and normal gallbladders (0%). There 
was a trend suggestive of increasing metallothionein expression with 
increasing histological dedifferentiation of carcinoma of the gallbladder. The 
increased expression of metallothionein in cases of carcinoma of the 
gallbladder may represent an increased exposure to heavy metals, which are 
known carcinogens, and may have a role in gallbladder carcinogenesis. They 
speculated that metallothionein over-expression in carcinoma of the 
gallbladder may be relevant to the poor prognosis and chemo-resistance 
seen in these cases (Shukla et al., 1998a). 
Heavy metal exposure and association with cancer 
Although there is no clear definition of what a heavy metal is, density in most 
cases is taken as the most important factor. Heavy metals are commonly 
defined as having a specific density of greater than 5gm/cm3. The main 
health hazards from heavy metal exposure are associated with lead, 
cadmium, mercury and arsenic. Heavy metals have been used in many 
different aspects of civilization for thousands of years. Lead has probably 
been used for nearly 5000 years with quite extensive use in ancient Rome. 
Famous artists like Claude Monet used cadmium pigments extensively in 
the1800s (Jarup, 2003). Although adverse effects of heavy metals have been 
known for a long time, environmental exposure to heavy metals continues 
and is even increasing. Since the middle of the 19th century, production of 
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heavy metals has increased steeply for more than 100 years with 
concomitant emissions to the environment (Figure 6.3) (Jarup, 2003). 
 
At the end of the 20th century, heavy metal emission started to decrease in 
developed countries. In the UK, emission of heavy metals fell by over 50% 
between 1990 and 2000.  
 
 
Figure 6.3: Global production and consumption of selected toxic metals, 1850–1990 
(Jarup, 2003) 
 
Heavy metal pollution can occur via different routes. The main sources of 
pollution are through air (during combustion in factories), surface water 
(effluent from storage and industry) and to soil and subsequently to 
groundwater and crops. Atmospheric emissions tend to be of greatest 
concern to human health, mainly because of widespread dispersion. The 
spatial distribution of cadmium and lead emission is shown below (Figure 
6.4, Figure 6.5) (http://www.msceast.org/hms/emissions.html). 
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Figure 6.4: Spatial distribution of natural cadmium emissions in Europe in 2007, 
g/km2/y 
 
 
 
Figure 6.5: Spatial distribution of natural lead emissions in Europe in 2007, kg/km2/y 
 
 
A population may be exposed to harmful chemical, physical and biological 
agents in air, food, water or soil. However, exposure does not result only 
from the presence of a harmful agent in the environment. There must be 
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contact between the agent and the outer boundary of the human body, such 
as the airways, the skin or the mouth. Exposure is often defined as a function 
of concentration and time: “an event that occurs when there is contact at a 
boundary between a human and the environment with a contaminant of a 
specific concentration for an interval of time” (Jarup, 2003). 
 
In our study we are more interested in the possible carcinogenic effects of 
heavy metals.  Non-carcinogenic adverse health effects of different heavy 
metals are excluded from discussion. Several metals and their compounds 
have been recognized as carcinogens: arsenic, beryllium, cadmium, 
chromium, cobalt, nickel and lead. The main route of exposure for most 
metals is inhalation and the main target organ is the lung. With the exception 
of hexavalent chromium, carcinogenic metals are weak mutagens, if at all, 
and their mechanisms of carcinogenicity are still far from clear. A general 
feature of arsenic, cadmium, cobalt and nickel is their property to enhance 
the mutagenicity and carcinogenicity of directly acting genotoxic agents. 
These properties can be interpreted in terms of the ability of these metals to 
inhibit the repair of damaged DNA. However, because carcinogenic metals 
cause tumor development in experimental animals even without other 
carcinogens, alternative mechanisms must be considered. There is evidence 
that carcinogenic metal compounds alter patterns of gene expression leading 
to stimulated cell proliferation, either by activation of early genes (proto-
oncogenes) or by interference with genes down-regulating cell growth 
(Beyersmann, 2002).  
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Both scientific committees and regulatory agencies classify carcinogens. The 
table below summarizes classification of some metals and metalloids by the 
International Agency for Research on Cancer ((IARC)) and German 
Commission for the Investigation of Health Hazards of Chemical Compounds 
in the Work Area (MAK commission). The IARC classifies the carcinogens 
according to carcinogenic hazard as carcinogenic to humans (Group 1), 
probably carcinogenic to humans (Group 2A), possibly carcinogenic to 
humans (Group 2B) or not classifiable as to its carcinogenicity to humans. 
The German MAK-commission also has classified several metals either as 
carcinogenic to humans (category 1), as considered to be carcinogenic to 
man based on long-term animal studies (category 2) or as giving concern to 
cause cancer, but evidence is not sufficient for classification in group 1 or 2 
(category 3B) (Beyersmann and Hartwig, 2008) (Table 6.1). 
 
Metals can be carcinogenic in the form of free ions, metal complexes, or 
particles of metal and poorly soluble compounds. The toxicity of metals 
depends on their physicochemical properties. Regarding pure metal ions, 
their oxidation state, charge and ionic radii are crucial. With metal 
complexes, their coordination number, the geometry and type of ligands are 
important for their toxic mechanism. Not only toxic metal cations, but also 
essential transition metal ions bind to biological ligands of opposite charges, 
such as amino acid side chains of proteins and phosphate groups of 
neocleotides and nucleic acids, and form complexes with oxygen, sulphur 
and nitrogen groups of proteins, nucleic acids and other biomolecules. 
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Table 6.1: Classification of metals and/or their compounds as carcinogenic. Source: 
International Agency for Research on Cancer ((IARC)) Monographs, MAK (German 
Commission for the Investigation of Health Hazards of Chemical Compounds in the 
Work Area). (ø, not classified) 
 
 
example, Cd2+ ions have ionic radii very similar to those of Ca2+. Although the 
preferred ligand of Ca2+ is oxygen, whereas Cd2+ prefers sulfur, Cd2+ also 
accepts oxygen and is able to substitute Ca2+ in protein binding sites. Cd2+ 
interferes with functions of numerous Ca2+-transport and Ca2+-dependent 
signalling proteins. In some cases substitution of Ca2+ by Cd2+ may even 
yield the normal protein function such as in the protein calmodulin where this 
substitution preserves 90% activity with cyclic phosphodiesterase (Cheung, 
1984, Beyersmann and Hartwig, 2008). Cd2+ also have an analogous 
electron configuration with Zn2+ and can substitute Zn2+ in zinc enzymes and 
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alter the biochemical functions of such proteins. Similarly lead (Pb2+) also 
interferes with many Ca2+-regulated biochemical systems. 
General mechanism of metal carcinogenicity 
The toxicity of metals and their compounds largely depend on their 
bioavailability, i.e. the mechanism of uptake through cell membranes, 
intracellular distribution and binding to cellular macromolecules. The anionic 
compounds of chromium and vanadium smoothly penetrate into cells via the 
general anion channel of the plasma membrane. Hence, anionic 
chromium(VI) is readily taken up into cells but as soon as it is reduced to 
chromium(III) by intracellular reducing agents, the metal accumulates in the  
 
Figure 6.6: Cellular uptake, intracellular distribution and binding of soluble and 
particulate metal compounds (Beyersmann and Hartwig, 2008) 
 
intracellular compartment (Cupo and Wetterhahn, 1985). Many toxic metals 
as divalent cations can penetrate the plasma membrane via cation 
cotransporters. In addition, soluble metal compounds may be taken up by 
phagocytosis leading to intracellular accumulation (Figure 6.6). 
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There appear to be three common pathways that contribute to the 
mechanism of carcinogenicity in majority of the metals, namely oxidative 
stress, DNA repair modulation and disturbances of signal transduction 
pathways. 
Induction of oxidative stress 
 
Oxidative stress is an interesting hypothesis to explain mutagenic and 
carcinogenic effects of metals. Ions of suspected carcinogenic metals like 
nickel and cobalt are capable of performing redox reactions in biological 
systems. They can induce formation of reactive oxygen and nitrogen species 
in vivo and vitro. Formation of hydroxyl radicals has been detected in 
experimental models and these radicals can cause oxidative damage to 
lipids, protein and DNA (Figure 6.7). Although ions of cadmium are not 
capable of inducing the same redox reaction in vivo, they can also generate 
oxidative stress through a different pathway. Cadmium can inhibit 
antioxidative enzymes in vivo and in vitro. Cadmium has been shown to 
inhibit catalase, superoxide dismutase, glutathione reductase and glutathione 
peroxidase. Apart from generating DNA damaged directly, reactive oxygen 
species at low concentrations function as mitogenic signals and active redox 
sensitive transcription factors (Genestra, 2007). Therefore, oxidative stress 
can initiate tumour development by mutagenesis and also deregulate cell 
growth and promote tumour growth. 
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Figure 6.7: Metal ions and oxidative stress. Modified from (Beyersmann and Hartwig, 
2008)  
 
One argument against oxidative stress hypothesis of metal carcinogenicity is 
the discrepancy between the comparatively high, often cytotoxic doses of 
metal compounds that are required to evoke the formation of reactive oxygen 
species and the measurable increase in cellular structures and the often very 
low doses of metals that can induce tumours. It probably supports the 
possibility that the whole mechanism of carcinogenicity is multi factorial.  
Interference with DNA repair 
Carcinogenic metals are considered only weak mutagens in mammalian cells 
and often inactive in bacterial assays. Mutagenicity in bacterial assay is an 
indicator of reactivity of a substance with DNA, metals are thought to exert 
genotoxicity by indirect mechanism. They often show the mechanism of 
comutagenicity, i.e. they enhance the mutagenicity of other genotoxic agents. 
There are 4 main, partly overlapping DNA repair pathways in mammalian 
cells: base excision, mismatch, nucleotide excision and recombinational 
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repair. Either inherited or acquired defects of these pathways can initiate 
malignant growth. These pathways are possibly targeted by toxic metals and 
inhibition of repair and persistent DNA damage results in genomic instability, 
which may become more significant under conditions of cell proliferation 
(Beyersmann and Hartwig, 2008).  
 
Deregulation of cell proliferation 
Tumour development is characterized by deregulation of cell growth and 
differentiation. Carcinogenic metals alter cell growth by different 
mechanisms, either affecting the growth stimulating factors or inactivating 
growth control mechanisms. Some metal ions can induce expression of 
cellular proto-oncogenes and modify pattern of gene expression. Changes in 
gene regulation precede formation of tumours. Some metal carcinogens 
have been shown to inactivate tumour suppressor protein p53. Finally, metal 
ions can deregulate cell proliferation by inactivating apoptotic processes 
resulting in adaptation to the cytotoxicity of the metal (Beyersmann and 
Hartwig, 2008).  
Cadmium and its role in pancreatobiliary malignancy 
Human cadmium exposure is associated with cancers of the lung and 
kidney((IARC), 1993). Cadmium is a toxic metal occurring in the environment 
naturally and as a pollutant from industrial and agricultural sources. Smoking 
is one of the major source of cadmium inhalation and food and water are the 
main source in the non-smoking population. Cadmium is efficiently retained 
in the kidneys with a very long half life of 10 – 30 years, although cadmium is 
nephrotoxic and initially causes renal tubular damage. Cadmium occurs 
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naturally in ores together with zinc lead and copper. Cadmium compounds 
are used as stabilizers in PVC products, colour pigment, several alloys and 
most commonly, in-rechargeable nickel cadmium batteries. Cadmium is also 
present as pollutant in phosphate fertilizers. European Union (EU) cadmium 
usage has decreased considerably during the 1990s, mainly due to phase 
out of cadmium products other than Ni-Cd batteries and the implementation 
of more stringent EU environmental legislations. In spite of these changes in 
Europe, overall cadmium production, consumption and emissions to the 
environment worldwide has increased dramatically in the 20th century. 
Having a long half-life in the human body, the adverse effects of increased 
cadmium exposure will only be apparent at a later stage. Cadmium 
containing products are rarely recycled and frequently dumped together with 
household waste, thereby contaminating the environment (Jarup, 2003). 
 
Cigarette smoking is a major source of cadmium exposure. The serum 
concentration of cadmium in smokers are on an average 4 – 5 times higher 
than those of non-smokers (Jarup et al., 1998). Food is the main source of 
cadmium in the general non-smoking population. Cadmium is present in 
most foodstuffs, but the concentration is highly variable. Gastrointestinal 
absorption of cadmium may be influenced by nutritional factors, such as the 
iron store (Flanagan et al., 1978). Serum cadmium levels generally reflect 
current exposure, but the cadmium concentration in the urine is influenced by 
the lifetime body burden and is proportional to the renal concentration of 
cadmium.  
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As part of our study, we are interested in the possible carcinogenic role of 
cadmium, especially its role in pancreatobiliary malignancy. As noted earlier, 
human cadmium exposure may be associated with cancers of the lung and 
kidney. In animals, cadmium induces carcinoma of lung after inhalation and 
cancers of the prostrate after ingestion of cadmium (Waalkes, 2003). 
Carcinogenicity of cadmium is due to multiple factors as explained earlier, i.e. 
indirect induction of oxidative stress, inhibition of DNA repair and 
deregulation of cell proliferation. In addition, cadmium has a unique 
mechanism of disruption of the cadherin mediated cell-cell adhesion system 
and cell-cell communication. Cadmium specifically displaces calcium from 
the protein E-cadherin (Prozialeck et al., 2003) and impair the cell-cell 
adhesion thereby deregulating cell proliferation.  
 
There is very little literature about possible carcinogenic effect on 
pancreatobiliary malignancy. In recent years some work has been done to 
look at possible association between occupational or environmental 
exposure to cadmium and pancreatic cancer in areas of high incidence of 
this disease. There are several risk factors implicated for pancreatic cancer 
but  they can be generally grouped in 4 categories:  
1. Smoking 
2. Chronic pancreatitis and genetic predisposition 
3. Diabetes mellitus and micro and macronutrients 
4. Occupational and environmental exposure to carcinogens 
There is a lack of publications looking at the possible environmental 
exposure and pancreatic cancer. Ojajärvi et al. in a meta-analysis tried to 
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consolidate epidemiological data on pancreatic cancer and worksite 
exposure (Ojajarvi et al., 2000). Over a long period from 1969 to 1998, they 
looked at 92 publications covering 161 different population groups, looking at 
23 agents or group of agents. Exposure to chlorinated hydrocarbon(CHC), 
nickel, chromium, polycyclic aromatic hydrocarbons and organochlorine 
insecticides were found to be associated with increased risk of pancreatic 
cancer. In this meta-analysis, cadmium compounds had very weak or no 
association with pancreatic cancer. The same group published in 2007 
applying a hierarchical Bayesian meta-analysis model and identified CHC as 
the agent that is associated with increased risk of pancreatic cancer (Ojajarvi 
et al., 2007). 
 
The strongest evidence of association between cadmium exposure and 
pancreatic cancer emerged from the East Nile Delta region of Egypt. This 
region exhibits a high incidence of early onset pancreatic cancer. The 
incidence of pancreatic cancer in this region for patients younger than 65 
years is more than twice as high as those  observed in Americans in the 
same age group and significantly higher than those seen in other parts of 
Egypt (Soliman et al., 2002). The reason for such a high incidence of early-
onset pancreatic cancer in this region is unclear. There is no good evidence 
that the first 3 risk factors for pancreatic cancer noted above would 
preferentially affect the residents of this region relative to rest of Egypt. 
However, it is well documented that this region has one of the highest levels 
of environmental pollution in Egypt.  
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Kriegel at al. conducted a pilot study in this region of Egypt to assess serum 
cadmium level as marker of exposure in pancreatic cancer patients and 
compare it with non-cancer patients from the same region. Nile river water is 
seriously contaminated with heavy metals, pesticides and hydrocarbons due 
to discharge of untreated industrial waste. High concentration of heavy 
metals, including cadmium is pollutants in the water. Plants and fish that 
grow in this water are also contaminated by these metals, which in turn 
accumulate in humans that feed on these contaminated foods. The serum 
cadmium level of residents of this region is about 10 times that of residents 
from cadmium polluted areas in Cairo and about 32 times higher than 
reference levels for the healthy population in the United States (Kriegel et al., 
2006). As discussed before, cadmium has a carcinogenic effect 
demonstrated both in vivo and in vitro and the 2 main risk factors of 
pancreatic cancer, namely smoking and age, are also associated with higher 
cadmium levels in the body. In this pilot study, serum cadmium levels and the 
occupation of farming were strong independent risk factors for pancreatic 
cancer.  
 
Suspicion of a strong association between cadmium exposure and 
pancreatic cancer has been reported from Louisiana (Lemus et al., 1996). 
Industrial activity along the Mississippi River has led to an accumulation of 
contaminants downstream in southern Louisiana (Mielke et al., 2000). 
Louisiana residents are exposed to environmental cadmium by inhalation. 
Lemus et al have shown that 64 out of 315 samples (20.3%) of indoor and 
outdoor air from 53 households in Louisiana exceeded the U.S. 
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Environmental Protection Agency’s permissible levels for cadmium (Lemus et 
al., 1996). Seafood and rice are popular food items in the local diet and both 
rice and fish harvested from cadmium-polluted areas contain high levels of 
cadmium. A case-control study from Louisiana showed significantly 
increased risk of pancreatic cancer associated with rice consumption among 
Cajuns, with a dose-response relationship (Falk et al., 1988, Falk et al., 
1990). More recent studies based on the same population have shown an 
increased risk of pancreatic cancer with increased urinary cadmium 
concentration (Luckett et al., 2012).  
 
Evidence is less convincing for an association of heavy metals and biliary 
cancers (gallbladder cancer and cholangiocarcinoma). The only evidence is 
available from an area of high incidence of gallbladder cancer and heavy 
industrial pollution in Northern India. In a case control study, Shukla et al 
demonstrated higher mean concentrations of cadmium, chromium and lead 
in the bile of patients with gallbladder cancer compared to a non-cancer 
group (Shukla et al., 1998b). A review article by Pandey et al. emphasized 
very little evidence on role of environmental pollutants in gallbladder cancer 
and highlighted the need for a robust epidemiological study (Pandey, 2006). 
 
Report from the same region of India suggested an association between 
serum copper and zinc level and gallbladder cancer. In a study comparing 
patients with gallbladder cancer and  benign biliary disease, the mean serum 
zinc levels were significantly lower in patients with carcinoma of the 
gallbladder than in patients with cholelithiasis and in healthy controls. The 
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mean serum copper levels were significantly higher in patients with 
carcinoma of the gallbladder as compared to patients with cholelithiasis and 
healthy controls. Biliary and tissue zinc levels were significantly lower in 
patients with carcinoma of the gallbladder than in patients with cholelithiasis. 
Biliary and tissue copper levels were higher in patients with carcinoma of the 
gallbladder than in patients with cholelithiasis (Gupta et al., 2005). Copper is 
an essential metal and plays the role of a co-factor for many biochemical 
reactions as a catalyst. Catalytic copper, because of its redox activity, can 
potentially play a central role in the formation of reactive oxygen species that 
bind rapidly to DNA causing DNA damage and thereby leading to 
carcinogenesis (Theophanides and Anastassopoulou, 2002). The present 
study, however, shows a higher concentration of copper in the bile of the 
malignant group and this is against the finding of Gupta et al. (2005) in the 
study discussed above. 
 
In recent years prospective data collected from the Third National Health and 
Nutrition Examination Survey (NHANES III) in the Unite States has been 
used to investigate the relationship between cadmium exposure and cancer 
mortality and association of specific cancers with cadmium exposure in the 
general population (Adams et al, 2012). The cadmium exposure of the study 
population was assessed by measuring a spot urine sample collected from 
participants and assayed for cadmium and creatinine. Urinary cadmium 
concentration is a reliable marker of long term cadmium exposure (Lauwerys 
et al, 1994). Cadmium concentration was divided by creatinine to correct for 
variation in hydration and was recorded as creatinine-normalised urinary 
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cadmium (uCd, µg/g). The study observed association between uCd and 
cancer mortality in both men and women. This association with total mortality 
as well as cancer specific mortality was stronger in men than in women. This 
study also observed association between cadmium exposure and pancreatic 
cancer as reported in earlier studies (Schwartz et al, 2000) from occupational 
cohorts. Since cigarettes are a major source of cadmium among smokers 
and a cause of pancreatic cancer, the authors restricted the analysis to 
never-smokers and the association of uCd with pancreatic cancer remained. 
Therefore, the association of cadmium exposure to pancreatic cancer is 
possibly independent of smoking. Even low to moderate cadmium exposure, 
as measured in urine, was associated with mortality from overall, smoking-
related, lung and pancreatic cancer in American-Indian adults who 
participated in the Strong Heart Study during 1989 to 1991 and followed up 
for 20 years (Garcia-Esquinas et al., 2014).  
 
Cadmium exposure induces lung and pancreatic cancer in experimental 
rodent models (Huff et al., 2007, Waalkes, 2003). In vitro, chronic cadmium 
exposure to human pancreatic duct epithelial cells can result in malignant cell 
transformation with increased secretion of metalloproteinases, increased 
invasiveness and increased colony formation (Qu et al., 2012).  
Environmental pollution in the North-East of England 
Compared to areas of heavy industry and pollution along the rivers Nile, 
Mississippi and Ganges, river basins in the UK are areas of relatively low 
environmental pollution. However, one cannot ignore that several of these 
river basins, especially in the North of England, were areas of mining 
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activities and that in itself can lead to metal pollution downstream. Some of 
these basins are still areas of heavy industry, for example Teesside region in 
the North-East of England. In our study, although there was a significantly 
higher level of lead and cadmium in the cancer group, no significant regional 
variation was noted and there was no suggestion that areas of heavy 
industry like Teesside had a higher incidence of pancreatobiliary malignancy. 
However, this study was not adequately powered to look at this aspect.  
 
Pless-Mulloli at al (Pless-Mulloli et al., 1998) assessed whether deprived 
populations living close to industry experience greater mortality from lung 
cancer than populations with comparable socioeconomic characteristics 
living further away in the North-East of England. Analysis was based on 2 
areas; Teesside and Sunderland. Housing estates in Teesside were selected 
based on socioeconomic criteria and distinguished by proximity to steel and 
chemical industries; they were then grouped into 3 zones, i.e. near (A), 
intermediate (B) and further (C). The estates in Sunderland were grouped 
into a single zone (Figure 6.8). 
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Figure 6.8: Estates selected for the analysis of mortality and survey data. Zone A, B 
and C indicate varying proximity to industry (Byrnes and Afdhal, 2002). 
 
 
Mortality from lung cancer was well above national average in all zones. For 
men a weak gradient corresponding to the proximity to industry at younger 
age reversed at older age. In women between 0 to 64 yrs of age, a stronger 
gradient in lung cancer mortality corresponded with proximity to industry 
across zones A, B and C. Overall rates in Teesside were higher than 
Sunderland rates for women aged 0 - 64 yrs. The association between 
increased lung cancer mortality and proximity to industry in women under 75 
years could not be explained by smoking, occupation, socio economic factors 
and occupation. Explanations for differences between men and women may 
include gender specific occupational factors and smoking patterns. The 
authors felt that the observed gradient in women points to a role for industrial 
air pollution. 
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The UK Environment Agency has recently published a report entitled 
Assessment of Metal Mining-Contaminated River Sediments in England and 
Wales (Science Report: SC030136/SR4, November 2008). The Environment 
Agency is the leading public body protecting and improving the environment 
in England and Wales and their work includes assessing and reducing the 
impact of industry on the environment. 
 
Many river basins in England and Wales have been significantly 
contaminated with metals released from past mining operations. The Water 
Framework Directive (WFD) River Basin Characterisation exercise in 2005 
estimated that 453 surface water bodies in seven of the eleven River Basin 
Districts were at risk of pollution by abandoned mines including coal mines. 
The peak period of metal mining was the mid to late 19th century, although 
pollution continued to be discharged from many sites. In the catchments, as 
much as 90% of the metals are associated with sediments rather than in 
aqueous form, and metal contaminants are mobilized and transported 
downstream and deposited by the river processes. This has created a 
collection of highly contaminated sediments, often a considerable distance 
downstream from the mines themselves. The report by the Environment 
Agency set out to use data from selected catchments to test the potential 
environmental impact of these contaminated sediments. It did not attempt to 
ascertain acceptable contaminant concentration in soil or water. Therefore, 
the report highlights the hazards associated with metal contaminated 
sediments and soil, but it did not evaluate the consequent risk. Over 
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thousands of years many tonnes of metals have been extracted from several 
major mining areas in the UK (Figure 6.9). 
 
Figure 6.9: Metal mining areas of England and Wales 
((Dunham et al., 1978) 
The last major mine closed in the late twentieth century and currently there 
are no operating metal mines in England and Wales. Early mining methods 
were primitive. Separation of metal sulphide ore minerals were carried out by 
crushing and gravity sorting in nearby streams, and in many areas solid and 
liquid mining effluents were disposed off directly into the nearest river. In 
some areas, especially in North Pennines and Yorkshire Dales, a hydraulic 
form of mining known as “hushing” was carried out by constructing dams 
upslope of mineral veins, then opening sluices to release water that eroded 
overburdened and exposed metal ores for easy excavation. The resulting 
torrent exposed underlying bedrock and mineral veins, which were worked 
using simple quarrying methods. All these methods involved water and led to 
the transfer of significant quantities of metal rich sediments to the river 
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systems. The table below lists the river catchments most affected by mining 
related metal contamination (Table 6.2). 
 
Table 6.2: River basins most affected by metal mining in England and Wales 
(Hudson-Edwards et al., 2008) 
 
In England and Wales, discharge of metal-enriched mine drainage water is 
common, not only from metal mines, but also from coalmines, which is a very 
important factor in the North-East of England. Studies on uptake of cadmium, 
lead and zinc concentrations by plants and crops growing on metal 
contaminated flood plains in England and Wales have shown that the plants 
and crops contain high concentration of these metals which exceeded 
concentrations in plants from uncontaminated areas (Macklin and Lewin, 
1989). 
 
In spite of large number of mining related contaminated river systems in the 
world, the exact nature of its effect on human population living beside, and 
relying on, these rivers for food and drinking water is relatively unknown. 
Several studies have measured the concentration of metals in river systems 
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affected by metal mining in England and Wales (Macklin and Dowsett, 1990, 
Macklin and Lewin, 1989). Some of the most intensely studied catchments 
are the rivers flowing to North Sea, which drain the Northern Pennines and 
Yorkshire Dales. River waters in these catchments exhibit high dissolved 
cadmium, lead and zinc concentration. This is mainly due to contamination 
from old mining areas upstream, although industrial activity, sewage 
treatment and atmospheric fallout also contribute (Table 6.3). This is highly 
relevant to the present study since individuals in these areas are within the 
catchment area of the Freeman Hospital for hepato-biliary and pancreatic 
diseases. 
 
The Environment Agency proposes a scheme to assess contaminated 
sediments and soils in metal mining affected rivers in England and Wales. 
The scheme involves: 
1. Identify catchments potentially impacted by sediment/water-borne 
metal contamination. 
2. Assess the extent and magnitude of contamination 
3. Carry out risk assessments in areas identified above to fully 
investigate source-pathway-receptor relationship 
4. Develop and implement contaminant monitoring and remediation 
programmes if risks are unacceptable. 
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Table 6.3: Dissolved metal concentration in water samples from some mining 
impacted English and Welsh rivers. Values in bold exceed the environment quality 
standard (EQS) (Hudson-Edwards et al., 2008) 
 
The Environmental Agency is already carrying out identification of 
catchments at risk from sediment-borne metal contamination. The WFD 
River Basin Characterisation maps, and investigation on non-coal mines 
should be used to identify catchments potentially impacted by contamination 
(Figure 6.10) (Jarvis et al., 2008, Hudson-Edwards et al., 2008). 
 143 
 
Figure 6.10: Map showing catchments of England and Wales  with likely (‘at risk and 
‘probably at risk’) to have sediment-borne, mining related metal contamination (after 
Environment Agency, 2008) 
 
Once the potentially impacted catchments are identified, the next step will be 
to assess the extent and magnitude of contamination. This would involve a 
detailed look onto the mining history of the area and the geomorphology of 
the catchments. The Environment Agency’s Indicative Floodplain Maps can 
be used to delineate river corridors and extent of contamination. Two 
examples are given below on the use of these flood maps (Figure 6.11, 
Figure 6.12). 
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Figure 6.11: Geomorphology and sediment-borne metal concentrations along River 
Swale, North-East England (Brewer et al., 2005) 
 
 
Figure 6.12: Example of floodplain map showing probability of contamination along 
River Swale (Brewer et al., 2005) 
 
The above discussion and the report by Environment Agency have 
highlighted the significantly elevated concentrations of metals such as 
cadmium, lead and zinc in river sediments and floodplain soils and in river 
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water as a result of now abandoned metal-mining activity. The Environment 
Agency recommended close monitoring of the effect of this contamination 
and its impact on the environment and health. Our project to look at the 
possible association of metal exposure and development of pancreatobiliary 
cancer will make a definite contribution to understand the impact on health 
due to environmental pollution, which is an extremely important issue in both 
developed and developing countries. 
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7. Conclusion and the Future of the Project 
 
It has been emphasised in the discussion that environmental pollution with 
metals has gradually gained considerable importance. The association 
between different heavy metal contamination of the environment and cancer 
has been investigated for a long time but no direct cause and effect 
relationship has yet been established. Heavy metals such as lead, cadmium, 
mercury, arsenic etc have been extensively studied and their effects on 
human health regularly reviewed by international bodies such as the WHO, 
including possible contribution to the aetiology of different types of cancers. 
 
The emphasis of this project was on a very specific type of cancer, i.e. 
pancreatobiliary malignancies. As demonstrated in our results section, this 
group of cancers is by no means homogeneous and comprises pure 
pancreatic cancers, pure biliary cancers (gallbladder cancers or 
cholangiocarcinoma) and periampullary cancers, where the cell of origin can 
be from pancreatic, biliary or intestinal epithelium. There is considerable 
evidence to show that clinically and prognostically, each subset behaves in a 
different way. It is very interesting to note, however, that anatomically these 
lesions are very close together and one would expect that the cells are 
exposed to similar environmental effects. In other words, any possible 
environmental influence on the aetiology of these tumours is likely to 
influence all the different subsets of the disease.  
 
In recent years, 2 important developments occurred which increased our 
interest in heavy metals and pancreatobiliary cancers. One was the evidence 
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generated by organizations like the Environment Agency that there is definite 
evidence of heavy metal contamination of the environment in this country. 
The second development was the emerging evidence of the association of 
heavy metals and malignancy from different parts of the world. Evidence 
from Egypt, India and United States regarding the association of cadmium 
and lead with pancreatic cancer were the first suggestions of an association 
between heavy metals and pancreatobiliary malignancy. This is also 
supported by the high cadmium content in tobacco, which is a definite risk 
factor for pancreatic cancers. 
 
Compared to the above-mentioned countries, the degree of environmental 
pollution is much lower in the UK. But even from the North-East of England 
there are studies demonstrating an association between environmental 
pollution and lung cancer. The association between heavy metal pollution 
and pancreatobiliary malignancy has not been looked into in details in this 
country. 
 
We looked at the biliary concentration of the heavy metals in our study 
instead of serum or urinary concentration, which has been done in other 
similar projects. Our rational was that the metal, which is excreted in bile, is 
in direct contact with the cells that have eventually turned malignant and it 
seemed logical to look at the immediate environment of these cells to 
consider the influence of these metals on cell growth. 
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It is very important to note that the presence of cadmium or lead in 
significantly higher concentration in the malignant group of patients does not 
mean a cause and effect relationship between the concentration of these 
metals and the development of cancer. It suggests the association between 
the two and adds to the evidence that this association really exists. It also 
opens up the possibility of further research to confirm this association and to 
establish a cause and affect relationship if it exists. 
 
There are 2 major projects that can emerge out of the present one. One 
would be to carry out an experimental study in a controlled environment and 
expose commercially available biliary and pancreatic cell lines to different 
heavy metals to demonstrate possible genotoxic or mitogenic effects. The 
other project would be a detailed epidemiological study to look at all cancer 
patients from a particular catchment area, e.g the Tees River catchments 
and record their possible lifetime environmental exposure to different metals 
and correlate with the pollution data available from the Environment Agency. 
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8. Summary of Work in Public Domain 
 
1. Role of heavy metals in pancreato-biliary malignancy. Sen G, 
Mansfield SD, Gallagher PV, Green P, Rimmer D, Manas DM, 
Charnley RM. Oral presentation at the 6th World Congress of IHPBA 
at Washington DC, June 2-6, 2004 
2. Role of heavy metals in pancreato-biliary malignancy. Sen G, 
Mansfield SD, Gallagher PV, Green P, Rimmer D, Manas DM, 
Charnley RM. Presented at 6th Congress of the European Hepato-
Pancreato-Biliary Association, Heidelberg, Germany, May 25 – 28, 
2005 
3. Biliary heavy metal excretion and its association with pancreato-biliary 
malignancy. G Sen, S D Mansfield, P Green, D Rimmer, D M Manas, 
R M Charnley. Presented at the 8th Congress of the European 
Hepato-Pancreato-Biliary Association, Athens, Greece, June 18 – 20, 
2009 
4. Biliary heavy metal excretion and its association with pancreato-biliary 
malignancy. G Sen, S D Mansfield, P Green, D Rimmer, D M Manas, 
R M Charnley. Oral presentation at the 4th Alpine HPB Meeting, Italy, 
February 2009. Winner of Covidien Travel Bursary. 
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9. Appendix I (Consent Form) 
 
 
Name:     
D.O.B.     
Unit no:    
A study to investigate the causes of biliary tract cancers 
 
CONSENT FORM FOR OBTAINING BILE 
 
This is a consent form that you are asked to sign in order to take part in a 
research project. 
 
A doctor should have discussed the study with you and given you an 
information sheet before you sign this consent form. 
 
You should not feel pressurised to take part in this study; if you choose not to 
be included in the study, your care and treatment will not be affected. 
 
I agree to take part in the study of the causes of biliary tract cancers. I 
understand that bile will be taken during the normal course of my 
investigation and treatment. The bile will be stored and analysed later. As the 
results from the analyses will only be used for research purposes I 
understand that participants are not told of their individual results. 
 
I understand that the research may or may not be of direct benefit to me. 
 
I have received and read an information sheet about this study. 
 
 
Signature: .....................................................  Date:............................. 
 
Name: ..................................................... 
 
___________________________________________________________ 
 
To be completed by the person obtaining consent. 
 
I have explained the study and witnessed the signature. 
 
 
Signature: .................................................... Date:.................................. 
 
Name: ........................................................................................................... 
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10. Appendix II (Information Sheet for patients) 
 
 
A STUDY TO INVESTIGATE THE CAUSES OF BILIARY TRACT 
CANCERS 
 
INFORMATION FOR PATIENTS 
 
You have a problem with the biliary tract or gallbladder that requires 
investigation or treatment. We would be grateful if you could help in a 
research project where bile from the biliary system is obtained from you. We 
are interested in why cancers of the bile ducts develop. 
 
The biliary tract consists of tubes, the proper name is ducts, which drain the 
liver into the bowel. These ducts are present both inside and outside the 
liver. Cancers of the biliary tract are uncommon and it is uncertain why they 
develop. Many possible factors have been described as potential. 
 
Research from India has suggested that one of these factors may be heavy 
metals, such as lead or cadmium. It is not known if this could be an important 
factor in people who live in Britain. We would like to obtain a sample of your 
bile to test for the amount of heavy metals. The bile is obtained without any 
extra difficulty during the normal course of your investigations and treatment. 
 
Many diseases run in families, with some members of the family but not 
others developing the disease. It is unknown if biliary tract cancers run in the 
family or if there may be problems with the genes that may interact with the 
environment. New genetic problems are constantly being identified. We 
would like a sample of your blood to store, in case any tests in the future 
prove to be useful. The blood sample will only be used for genetic analysis in 
relation to biliary tract cancers. 
 
As the results from the analyses will only be used for research purposes 
participants are not told of their individual results. All information gathered will 
be treated as strictly confidential. No individual will be identified in any 
medical research literature resulting from this study. 
 
You do not have to participate in this study. If you choose not to be included 
in the study your care and treatment will not be affected. You are also quite 
free to change your mind and withdraw from the study at any time. 
 
If at any time you have any questions that you would like to ask regarding 
this study you should address them to Mr. R. M. Charnley, Consultant 
Surgeon (ext 26147) or  Mr. Gourab Sen, Clinical Fellow (Bleep 3393), the 
Department of Surgery, Freeman Hospital.  
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